GB Sciences (GBLX) 10-K 28 Aug 20 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Mar. 31, 2020	Aug. 28, 2020	Sep. 30, 2019
Document Information [Line Items]
Entity Registrant Name	GB SCIENCES INC
Entity Central Index Key	0001165320
Trading Symbol	gblx
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		280,532,686
Entity Public Float			$ 25.5
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(g) Security	Common Stock $.0001 Par Value

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Mar. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 151,766	$ 182,055
Accounts receivable, net of allowance for doubtful accounts of $130,378 and $66,748 at March 31, 2020 and 2019, respectively	117,967	488,329
Inventory, net	1,445,839	1,533,792
Prepaid expenses and other current assets	60,885	262,208
Note receivable	5,224,423
Current assets from discontinued operations		1,000,387
TOTAL CURRENT ASSETS	7,000,880	3,466,771
Property and equipment, net	5,533,833	10,481,706
Intangible assets, net of accumulated amortization of $12,287 and $3,745 at March 31, 2020 and 2019, respectively	1,699,966	1,818,802
Deposits and other noncurrent assets	91,504	230,651
Operating lease right-of-use assets, net	26,685
Non-current assets from discontinued operations		14,025,372
TOTAL ASSETS	14,352,868	30,023,302
CURRENT LIABILITIES:
Accounts payable	2,559,914	1,374,771
Accrued interest	397,652	142,112
Accrued liabilities	888,012	244,931
Notes and convertible notes payable, net of unamortized discount of $608,580 and $799,410 at March 31, 2020 and 2019, respectively	5,534,728	2,229,812
Indebtedness to related parties	586,512
Note payable to related party	151,923
Income tax payable	592,982	506,145
Operating lease obligations, current	7,265
Finance lease obligations, current	166,769	80,132
Current liabilities from discontinued operations		2,134,277
TOTAL CURRENT LIABILITIES	10,885,757	6,712,180
Note payable, net of unamortized discount of $0 and $13,928 at March 31, 2020 and 2019, respectively		161,072
Operating lease obligations, long term	22,515
Finance lease obligations, long term	3,533,090	3,646,540
Long term liabilities from discontinued operations		2,347,511
TOTAL LIABILITIES	14,441,362	12,867,303
Commitments and contingencies (Note 12)
STOCKHOLDERS' EQUITY:
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 275,541,602 and 240,627,102 at March 31, 2020 and 2019, respectively	27,554	24,063
Additional paid-in capital	97,271,157	93,020,015
Accumulated deficit	(97,387,205)	(84,743,836)
TOTAL GB SCIENCES, INC. STOCKHOLDERS' EQUITY/(DEFICIT)	(88,494)	8,300,242
Non-controlling interest in discontinued operations		8,855,757
TOTAL EQUITY/(DEFICIT)	(88,494)	17,155,999
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 14,352,868	$ 30,023,302

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Accounts receivable, allowance for doubtful accounts	$ 130,378	$ 66,748
Intangible assets, accumulated amortization	12,287	3,745
Notes and convertible notes payable, unamortized discount, current	608,580	799,410
Note payable, unamortized discount, noncurrent	$ 0	$ 13,928
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	275,541,602	240,627,102
Common stock, shares outstanding (in shares)	275,541,602	240,627,102

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Sales revenue	$ 3,120,620	$ 3,454,552
Cost of goods sold	(4,002,083)	(3,246,097)
Gross profit (loss)	(881,463)	208,455
General and administrative expenses	6,483,513	13,399,524
Loss on impairment of long-lived assets	4,645,054
LOSS FROM OPERATIONS	(12,010,030)	(13,191,069)
OTHER INCOME (EXPENSE)
Interest expense	(1,625,204)	(4,940,090)
Other expense	(194,248)	(3,368,556)
Loss on extinguishment	(216,954)
LOSS ON MODIFICATION OF NOTE RECEIVABLE	(1,895,434)
Gain on deconsolidation of subsidiary	4,393,242
Total other income/(expense)	461,402	(8,308,646)
LOSS BEFORE INCOME TAXES	(11,548,628)	(21,499,715)
Income tax expense	(86,837)	(526,145)
LOSS FROM CONTINUING OPERATIONS	(11,635,465)	(22,025,860)
Loss from discontinued operations	(1,476,220)	(2,654,427)
NET LOSS	(13,111,685)	(24,680,287)
Loss attributable to non-controlling interest	(738,106)	(1,027,122)
NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC.	(12,373,579)	(23,653,165)
Continuing operations	(11,635,465)	(22,025,860)
Discontinued operations	(738,114)	(1,627,305)
Net loss	$ (12,373,579)	$ (23,653,165)
Continuing operations (in dollars per share)	$ (0.05)	$ (0.10)
Discontinued operations (in dollars per share)		(0.01)
Net loss (in dollars per share)	$ (0.05)	$ (0.11)
Weighted average common shares outstanding - basic and diluted (in shares)	258,450,641	209,537,769

Statements of Stockholders' Equ

Statements of Stockholders' Equity/Deficit - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Noncontrolling Interest [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Mar. 31, 2018						168,616,855
Balance at Mar. 31, 2018						$ 16,862	$ 70,961,104	$ (58,229,235)	$ 2,882,990	$ 15,631,721
Issuance of stock for debt conversion (in shares)						18,563,885
Issuance of stock for debt conversion						$ 1,856	4,639,115			$ 4,640,971
Exercise of warrants for stock (in shares)						12,657,875				12,657,875
Exercise of warrants for stock						$ 1,266	3,919,454			$ 3,920,720
Issuance of stock for services (in shares)						4,032,407				4,032,407
Issuance of stock for services						$ 403	1,253,960			$ 1,254,363
Share based compensation expense							1,966,388			1,966,388
Issuance of stock for cash, net of issuance costs (in shares)						36,156,080
Issuance of stock for cash, net of issuance costs						$ 3,616	6,518,509			6,522,125
Beneficial conversion feature on notes payable							176,471			176,471
Contributions from non-controlling interest									6,999,889	$ 6,999,889
Stock issued to settle Pacific Leaf royalty agreement (in shares)						600,000				600,000
Stock issued to settle Pacific Leaf royalty agreement						$ 60	130,940			$ 131,000
Compensation warrants							592,638			592,638
Inducement dividend from warrant exercises							2,861,436	(2,861,436)
Net loss								(23,653,165)		(23,653,165)
Loss attributable to non-controlling interest									(1,027,122)	(1,027,122)
Balance (in shares) at Mar. 31, 2019						240,627,102
Balance (Accounting Standards Update 2016-02 [Member]) at Mar. 31, 2019			$ (7,550)		$ (7,550)
Balance at Mar. 31, 2019						$ 24,063	93,020,015	(84,743,836)	8,855,757	17,155,999
Issuance of stock for debt conversion (in shares)						7,583,333
Issuance of stock for debt conversion						$ 758	524,242			$ 525,000
Exercise of warrants for stock (in shares)						17,563,000				17,563,000
Exercise of warrants for stock						$ 1,756	1,155,971			$ 1,157,727
Issuance of stock for services (in shares)						2,100,000				2,100,000
Issuance of stock for services						$ 210	213,790			$ 214,000
Share based compensation expense							287,260			$ 287,260
Issuance of stock for cash, net of issuance costs (in shares)						7,668,167				7,668,167
Issuance of stock for cash, net of issuance costs						$ 767	717,929			$ 718,696
Beneficial conversion feature on notes payable							829,737			829,737
Contributions from non-controlling interest									590,000	590,000
Stock issued to settle Pacific Leaf royalty agreement
Compensation warrants							132,914			132,914
Inducement dividend from warrant exercises							262,240	(262,240)
Net loss								(12,373,579)		(12,373,579)
Loss attributable to non-controlling interest									(738,106)	(738,106)
Induced conversions of accrued interest on notes payable							127,059			127,059
Deconsolidation of GB Sciences Louisiana, LLC									(8,707,651)	(8,707,651)
Balance (in shares) at Mar. 31, 2020						275,541,602
Balance at Mar. 31, 2020						$ 27,554	$ 97,271,157	$ (97,387,205)		$ (88,494)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
OPERATING ACTIVITIES:
Net loss	$ (13,111,685)	$ (24,680,287)
Loss from discontinued operations	(1,476,220)	(2,654,427)
Net loss from continuing operations	(11,635,465)	(22,025,860)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	258,729	250,187
Stock-based compensation	287,260	1,966,388
Stock issued for services	214,000	1,254,363
Issuance of compensation warrants to brokers	132,914	592,638
Bad debt expense	108,001	5,849
Amortization of debt discount and beneficial conversion feature	1,150,995	793,820
Interest expense on conversion of notes payable	84,354	3,464,187
Noncash expense recorded for settlement of note payable and related royalty agreement (Note 6)		2,140,925
Loss on extinguishment of debt	216,954
Loss on disposal of assets and termination of operating lease	178,760	128,946
Loss on induced conversion of note payable	127,059
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down	4,645,054
Loss on modification of note receivable	1,895,434
Gain on deconsolidation of subsidiary	(4,393,242)
Interest income receivable and amortization of discount on note receivable	(509,265)
Changes in operating assets and liabilities:
Accounts receivable	412,498	172,895
Prepaid expenses and other current assets	51,186	869,210
Decrease in deposits and other noncurrent assets	139,147	120,089
Inventory	665,560	(16,971)
Increase (Decrease) in Accounts Payable, Total	781,589	1,002,846
Accrued expenses	707,158	38,780
Accrued interest	421,055	150,845
Income tax payable	86,837	506,145
Indebtedness to related parties	738,435
Net cash used in operating activities of continuing operations	(3,234,993)	(8,584,718)
Net cash used in operating activities of discontinued operations	(1,244,720)	(1,271,177)
Net cash used in operating activities	(4,479,713)	(9,855,895)
INVESTING ACTIVITIES:
Purchase of property and equipment	(202,297)	(1,512,094)
Proceeds from disposal of fixed assets	16,000
Acquisition of intangible assets	(91,862)	(414,041)
Net cash used in investing activities of continuing operations	(278,159)	(1,926,135)
Net cash used in investing activities of discontinued operations	(260,625)	(9,070,409)
Net cash used in investing activities	(538,784)	(10,996,544)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock	790,225	11,402,464
Proceeds from warrant exercises	1,274,790
Proceeds from convertible notes payable	2,630,000	1,500,000
Proceeds from line of credit	480,000
Brokerage fees for issuance of common stock and warrants	(188,593)	(959,620)
Fees for issuance of convertible note	(175,000)
Principal payments on debt and lease obligations	(106,049)	(690,827)
Cash paid for global settlement of note payable and related royalty agreement		(1,000,000)
Net cash provided by financing activities of continuing operations	4,705,373	10,252,017
Net cash provided by financing activities of discontinued operations	282,835	7,248,480
Net cash provided by financing activities	4,988,208	17,500,497
Net change in cash and cash equivalents	(30,289)	(3,351,942)
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS	182,055
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	227,758	3,579,700
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS	151,766	182,055
CASH AND CASH EQUIVALENTS AT END OF YEAR		227,758
Less: cash and cash equivalents classified as discontinued operations		(45,703)
Cash paid for interest	451,040	539,242
Cash paid for income tax		20,000
Non-cash transactions:
Stock issued upon conversion of convertible notes payable	525,000	4,640,971
Stock issued to settle royalty agreement		131,000
Depreciation capitalized in inventory	811,508	584,017
Induced dividend from warrant exercises	262,240	2,861,436
Patent filing and drafting costs capitalized in intangible assets	247,646
Property capitalized under operating leases	182,624
Cumulative effect of the new lease standard	7,550
Convertible Notes Payable [Member]
Non-cash transactions:
Beneficial conversion feature on notes payable	$ 829,737	$ 176,471

Note 1 - Background and Basis o

Note 1 - Background and Basis of Presentation	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1 Background GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) seeks to be a biopharmaceutical research and cannabinoid-based drug development company whose goal is to create patented formulations for safe, standardized, cannabinoid therapies that target a variety of medical conditions in both the pharmaceutical and wellness markets. The Company is is engaged in the research and development of cannabinoid medicines and plans to produce cannabinoid therapies for the wellness markets based on its portfolio of intellectual property. Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of cannabinoid medicines with virtual operations in North America and Europe. GBSGB assets include cannabinoid medicine intellectual property, research contracts and key supplier arrangements. GBSGB's intellectual property covers a range of conditions and several programs are in pre-clinical animal stage of development; including Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB's intellectual property portfolio includes two five four one 2020, three 28 We were incorporated in the State of Delaware on April 4, 2001, March 28, 2008, On March 13, 2014, April 4, 2014, Effective December 12, 2016, 8 October 14, 2016. Effective April 8, 2018, 250,000,000 400,000,000. August 15, 2019, 400,000,000 600,000,000. Recent Developments On April 7th, 2020, May 19, 2020, 10,653,640. On May 12th, 2020, July 14, 2020 10,709,670. On November 15, 2019, 50.01% $8,000,000 may $8,000,000 August 24, 2020, $5,224,423, $324,423 $4,900,000 October 15, 2020, $8,000,000 On November 15, 2019, 75% $3.0 $3.0 March 24, 2020, 100% $4.0 $4.0 8% 36 16 The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company's wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not November 27, 2019, 100% $300,000 16 The sales are expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevada has been subject to an indefinite moratorium since October 2019. July 21, 2020, 90 19 Intellectual Property Our intellectual property portfolio includes: Two USPTO Patents Issued/Allowed for Cannabinoid- and Myrcene-Containing Complex Mixtures Title: CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES U.S. Patent Number 10,653,640; Issued: May 19, 2020; October 23, 2038 Patent protection was granted for GBSGB's Cannabinoid-Containing Complex Mixtures for the treatment of Parkinson's disease. Title: MYRCENE-CONTAINING COMPLEX MIXTURES TARGETING TRPV1 U.S. Patent Number 10,709,670; Issued: July 14, 2020; May 22, 2038 Five USPTO & Twenty-Three International Patent Applications Pending Title: CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES U.S. Patent Application No. 15/729,565; PCT/US2017/055989 Filed: October 10, 2017; National stage applications entered in AU, CA, CN, EP, HK, IL, and JP on October 10, 2017. On April 3, 2020, No. 16/844,713, Apr 9, 2020, No. 62/406,764 October 11, 2016. Title: CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF MAST CELL-ASSOCIATED OR BASOPHIL-MEDIATED INFLAMMATORY DISORDERS U.S. Patent Application No.15/885,620; PCT/US2018/016296 Filed: January 31, 2018; National stage applications entered in AU, CA, CN, EP, HK, IL, and JP on January 31, 2018. Claims benefit of U.S. Patent Application No. 62/453,161 February 1, 2017. Title: MYRCENE-CONTAINING COMPLEX MIXTURES TARGETING TRPV1 U.S. Patent Application No. 15/986,316; No. PCT/US2018/033956 Filed: May 22, 2018; National stage applications entered in AU, CA, CN, EP, HK, IL, and JP on May 22, 2018. On May 12, 2020, TRPV1 No. 16/878,295, May 19, 2020, No. 62/509,546 May 22, 2017. Title: TRPV1 U.S. Patent Application No.: 16/420,004; No.: PCT/US2019/033618 Filed: May 22, 2019; Claims benefit of U.S. Patent Application Nos. 62/674,843 May 22, 2018; 62/769,743 November 20, 2018; 62/849,719 May 17, 2019. Title: THERAPEUTIC NANOPARTICLES ENCAPSULATING TERPENOIDS AND/OR CANNABINOIDS U.S. Patent Application No.:16/686,069 No.: PCT/ES2019/070765 Filed: November 8, 2019; Claims benefit of U.S. Patent Application Nos. 62/757,660 November 8, 2018 Two Provisional USPTO Patent Applications Pending Title: TREATMENT OF PAIN USING ALLOSTERIC MODULATOR OF TRPV1 U.S. Patent Application No.: 62/868,794; Filed: June 28, 2019 Title: THERAPEUTIC NANOPARTICLES ENCAPSULATING TERPENOIDS AND/OR CANNABINOIDS U.S. Patent Application No.: 62/897,235 Filed: September 6, 2019 Two Additional Provisional Patent Applications Filed on August 18, 2020 GBSGB has data sets for two August 18, 2020, Title: CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISORDERS Filing Date: August 18, 2020; Title: CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS Filing Date: August 18, 2020; Multiple Licensed Patents for GBSGB's Intellectual Property Portfolio Title: METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY. Inventor: Alexander Stokes; Assignee: University of Hawai'i Commercialization rights licensed to Makai Biotech, LLC Sublicensed by Makai Biotech, LLC to GBS Global Biopharma, Inc. Status: Granted in the following territories on the corresponding dates U.S. Patent Number: 9,084,786; July 21, 2015 U.S. Patent Number: 10,137,123; November 27, 2018 U.S. Continuation Application: 16/181,204 European Union Patent Number: 2,635,281; March 14, 2018 Europe Patent Application: 3,348,267 Hong Kong Patent Number: 14102182.8; March 14, 2018 India Patent Application: 1404/KOLNP/2013 China Patent Application: 201180063998.4 Title: METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION OF POLYMERIC NANOPARTICLES FOR TREATING NEUROPATHIC PAIN CAUSED BY PERIPHERAL NERVE COMPRESSION Inventors: Martin Banderas, Lucia; Fernandez Arevala, Mercedes; Berrocoso, Dominguez, Esther; and Mico Segura, Juan Antonio Assignees: Universidad de Sevilla, Universidad de Cadiz, and Centro de Investigacion Biomedica En Red (CIBER) Exclusive worldwide license held by GBS Global Biopharma, Inc. WIPO/PCT Application: PCT/ES2016/000016 No. 2016/128591 Filed: August 18, 2016 Claims benefit of Spanish Patent Application no. P201500129 No. 2582287 Filed: February 9, 2015 U.S. Patent Application: 15/549,653 Spain Patent ES2582287; September 29, 2017 Europe Patent Application: EP3257503 Canada Patent Application CA2976040

Note 2 - Going Concern

Note 2 - Going Concern	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 The Company's consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $ ( 97,387,205 March 31, 2020 ( 3,884,877 March 31, 2020 ( 3,245,409 ( 1,133,890 March 31, 2019. ( 4,479,713 ( 1,244,720 year ended March 31, 2020 ( 9,855,895 ( 1,271,177 year ended March 31, 2019 Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no In view of these conditions, the Company's ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not may

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3 Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. The subsidiaries of the Company are: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC ECRX, Inc. GB Sciences Texas, LLC GB Sciences Nopah, LLC GBS Global Biopharma, Inc. Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. The current and long-term capital lease obligations recorded in the consolidated balance sheet as of March 31, 2019 15 no Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The assets and liabilities associated with discontinued operations included in our consolidated balance sheets are as follows: Discontinued Operations – (continued) March 31, 2020 March 31, 2019 Continuing Discontinued Total Continuing Discontinued Total ASSETS CURRENT ASSETS Cash $ 151,766 $ - $ 151,766 $ 182,055 $ 45,703 $ 227,758 Accounts receivable, net 117,967 - 117,967 488,329 - 488,329 Inventory, net 1,445,839 - 1,445,839 1,533,792 602,714 2,136,506 Prepaid and other current assets 60,885 - 60,885 262,208 351,970 614,178 Note receivable 5,224,423 - 5,224,423 - - - TOTAL CURRENT ASSETS 7,000,880 - 7,000,880 2,466,384 1,000,387 3,466,771 Property and equipment, net 5,533,833 - 5,533,833 10,481,706 13,022,996 23,504,702 Intangible assets, net 1,699,966 - 1,699,966 1,818,802 - 1,818,802 Deposits and other noncurrent assets 91,504 - 91,504 230,651 1,002,376 1,233,027 Operating lease right-of-use assets, net 26,685 - 26,685 - - - TOTAL ASSETS $ 14,352,868 $ - $ 14,352,868 $ 14,997,543 $ 15,025,759 $ 30,023,302 LIABILITIES CURRENT LIABILITIES Accounts payable $ 2,559,914 $ - $ 2,559,914 $ 1,374,771 $ 1,695,985 $ 3,070,756 Accrued interest 397,652 - 397,652 142,112 - 142,112 Accrued expenses 888,012 - 888,012 244,931 76,415 321,346 Notes payable, net 5,534,728 - 5,534,728 2,229,812 300,000 2,529,812 Indebtedness to related parties 586,512 - 586,512 - - - Note payable to related party 151,923 - 151,923 - - - Income tax payable 592,982 - 592,982 506,145 - 506,145 Operating lease obligations, current 7,265 - 7,265 - - - Finance lease obligations, current 166,769 - 166,769 80,132 61,877 142,009 TOTAL CURRENT LIABILITIES 10,885,757 - 10,885,757 4,577,903 2,134,277 6,712,180 Note payable, net - - - 161,072 - 161,072 Operating lease obligations, long term 22,515 - 22,515 - - - Finance lease obligations, long term 3,533,090 - 3,533,090 3,646,540 2,347,511 5,994,051 TOTAL LIABILITIES $ 14,441,362 $ - $ 14,441,362 $ 8,385,515 $ 4,481,788 $ 12,867,303 The revenues and expenses associated with discontinued operations included in our consolidated statements of operations were as follows: For the Year Ended March 31, For the Year Ended March 31, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ 3,120,620 $ 569,077 $ 3,689,697 $ 3,454,552 $ - $ 3,454,552 Cost of goods sold (4,002,083 ) (574,544 ) (4,576,627 ) (3,246,097 ) - (3,246,097 ) Gross profit (loss) (881,463 ) (5,467 ) (886,930 ) 208,455 - 208,455 General and administrative expenses 6,483,513 1,292,613 7,776,126 13,399,524 2,403,259 15,802,783 Loss on impairment of long-lived assets 4,645,054 - 4,645,054 - - - LOSS FROM OPERATIONS (12,010,030 ) (1,298,080 ) (13,308,110 ) (13,191,069 ) (2,403,259 ) (15,594,328 ) OTHER INCOME/(EXPENSE) Interest expense, net (1,625,204 ) (178,140 ) (1,803,344 ) (4,940,090 ) (251,168 ) (5,191,258 ) Other expense (194,248 ) - (194,248 ) (3,368,556 ) - (3,368,556 ) Loss on extinguishment (216,954 ) - (216,954 ) - - - Loss on modification of note receivable (1,895,434 ) - (1,895,434 ) - - - Gain on deconsolidation of subsidiary 4,393,242 - 4,393,242 - - - TOTAL OTHER INCOME/(EXPENSE) 461,402 (178,140 ) 283,262 (8,308,646 ) (251,168 ) (8,559,814 ) NET LOSS BEFORE INCOME TAXES (11,548,628 ) (1,476,220 ) (13,024,848 ) (21,499,715 ) (2,654,427 ) (24,154,142 ) Income tax expense (86,837 ) - (86,837 ) (526,145 ) - (526,145 ) NET LOSS $ (11,635,465 ) $ (1,476,220 ) $ (13,111,685 ) $ (22,025,860 ) $ (2,654,427 ) $ (24,680,287 ) Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three no March 31, 2020 Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections. During the year ended March 31, 2020 $108,001 $63,630 $44,371 Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Indefinite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also include the acquisition cost of a cannabis production license with an indefinite life. We amortize our finite-lived intangible assets over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. During the year ended March 31, 2020 100% 16 not $449,801 $1,021,067 $571,266. Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and has lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3 8 not Long-Lived Assets Property and equipment comprise a significant portion of our total assets. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not During the year ended March 31, 2020 100% 16 not $8.0 $11.9 $7.3 4,645,054 3 820. 17%. $4.0 $4.0M Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, “Application of Issue No. 98 5 first 718 Compensation – Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company's only current revenue source is from sales of cannabis, a distinct physical good. Under ASC 606, may may one 606 not Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2020 2019 $1,543,397 $458,790 Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Loss per Share The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 158,404,020 128,608,852 March 31, 2020 2019 not Recent Accounting Pronouncements Recently Adopted Standards In June 2016, No. 2016 13, 326 2016 13" 326 326 326 2016 13 not not December 15, 2019, April 1, 2019. not In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, April 1, 2019. not All other newly issued accounting pronouncements but not not

Note 4 - Inventory

Note 4 - Inventory	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 4 Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress includes live plants and cannabis in the drying, curing, and trimming processes and extracts in process. Finished goods includes completed cannabis flower, trim, and extracts that are ready to be sold in bulk and packaged forms. March 31, 2020 March 31, 2019 Raw materials $ 91,465 $ 440,414 Work in progress 1,166,511 676,341 Finished goods 466,319 579,604 Subtotal 1,724,295 1,696,359 Allowance to reduce inventory to NRV (278,456 ) (162,567 ) Total inventory, net $ 1,445,839 $ 1,533,792

Note 5 - Leases

Note 5 - Leases	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Lessee, Operating and Finance Leases [Text Block]	Note 5 In February 2016, 2016 02, 842 Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the standard. Lease payments do not December 15, 2018 April 1, 2019. not The Company adopted the New Lease Standard using the modified retrospective transition approach as of the effective date as permitted by the amendments in ASU 2018 11, 842 not April 1, 2019. The Company determines if an arrangement is a lease at inception and has lease agreements for warehouses and equipment. These commitments have remaining non-cancelable lease terms, with lease expirations which range from 2024 2025 5 As a result of the adoption of ASC 842, $182,624, $190,173 April 1, 2019, Operating leases are presented in operating lease right-of-use assets, operating lease obligations, current, and operating lease obligations, long term on the consolidated balance sheets. Finance leases are included in property and equipment, finance lease obligations, current, and finance lease obligations, long term. ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. The rates used to discount finance leases previously recorded as capital leases range from 10.2% 11.5%. 17.0%. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not During the year ended March 31, 2020 679,347 426,374 252,973 75,306 27,611 47,695 Discontinued operations includes $ 280,227 153,977 126,250 Amortization of lease assets is included in general and administrative expenses. The future minimum lease payments of lease liabilities as of March 31, 2020 Year Ending Operating March 31, Finance Leases Leases 2021 $ 581,763 $ 11,779 2022 544,296 11,779 2023 560,625 11,779 2024 577,444 3,927 2025 594,767 - Thereafter 3,781,101 - Total minimum lease payments 6,639,996 39,264 Less: Amount representing interest (2,940,137 ) (9,484 ) Present value of minimum lease payments 3,699,859 29,780 Less: Current maturities of capital lease obligations (166,769 ) (7,265 ) Long-term capital lease obligations $ 3,533,090 $ 22,515

Note 6 - Notes Payable and Line

Note 6 - Notes Payable and Line of Credit	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 6 6% November 30, 2018 On July 28, 2018, $1 $1.5 August 31, 2018. Because the Amendment and Termination Agreement irrevocably terminated the Pacific Leaf Royalty Agreement, the Company recorded an expense of $1,530,000 September 30, 2018 December 31, 2018 February 2018 March 31, 2019. Contemporaneously with the Amendment and Termination Agreement, the Company issued a Promissory Note (“Promissory Note”) for the remaining $0.5 6% November 30, 2018. In consideration for deferring the payment of the amounts due to Pacific Leaf, the Company issued 100,000 July 31, 2018 $36,000. $1.0 August 2018 $36,000 $1,000,000 August 2018 March 31, 2019, On December 21, 2018, $100,000 $12,164 $87,836 On December 21, 2018, 500,000 $95,000 March 31, 2019, In total, the Company recorded $3.1 March 31, 2019, Amounts Recorded in Other Expense Year Ended Related to the Amendment and Termination Agreement March 31, 2019 Prepaid royalties recorded in February 2018 $ 1,530,000 Cash payments made in August 2018 1,000,000 Promissory note issued to Pacific Leaf, due on or before November 30, 2018 500,000 100,000 shares common stock issued to Pacific Leaf 36,000 Settlement of convertible note payable and related accrued interest (20,075 ) 500,000 shares common stock issued to Pacific Leaf on December 21, 2018 95,000 Total $ 3,140,925 The Company made additional payments on the promissory note of $100,000 January 16, 2019, $100,000 February 6, 2019, $210,000 March 4, 2019. $15,929 March 31, 2019. 0% October 23, 2017 On October 23, 2017, 100% 100% one $500,000 0% $700,000 three January 1, 2018. The present value of the note was $521,067 20.3% $178,933. March 31, 2020 $53,122 The Company has been in default on this note since June 2019, fifteen $291,660 10% $30,787 year ended March 31, 2020 ten $369,444, 16 0% December 20, 2018 On December 20, 2018, $300,000 Pursuant to the Loan Agreement, GBSLA began making eight 8 $33,333 10 th April 2019. November 15, 2019, $266,667 $33,333. 15 8% November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 ( 16 $470,000 year ended March 31, 2020 $480,000 $10,000. $10,444 year ended March 31, 2020 $480,000 March 31, 2020 Summary of Notes Payable As of March 31, 2020 As of March 31, 2020 Short-Term Notes Payable Face Value Discount Carrying Value 6% Convertible promissory notes payable (Note 7) $ 1,257,000 $ (155,340 ) $ 1,101,660 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 7) 1,271,863 (409,481 ) 862,382 8% Convertible Promissory Note dated April 23, 2019 (Note 7) 2,765,000 (29,830 ) 2,735,170 0% Note Payable dated October 23, 2017 (Note 6) 369,445 (13,929 ) 355,516 8% Line of Credit dated November 27, 2019 (Note 6) 480,000 - 480,000 Total Short-Term Notes Payable $ 6,143,308 $ (608,580 ) $ 5,534,728 As of March 31, 2019 As of March 31, 2019 Short-Term Notes Payable Face Value Discount Carrying Value 6% Convertible promissory notes payable (Note 7) $ 1,257,000 $ (564,929 ) $ 692,071 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 7) 1,500,000 (169,134 ) 1,330,866 0% Note Payable dated October 23, 2017 (Note 6) 272,222 (65,347 ) 206,875 Total Short-Term Notes Payable $ 3,029,222 $ (799,410 ) $ 2,229,812 0% Note Payable dated December 20, 2018 (discontinued operations) $ 300,000 $ - $ 300,000 Long-Term Notes Payable 0% Note Payable dated October 23, 2017 (Note 6) $ 175,000 $ (13,928 ) $ 161,072 Total Long-Term Notes Payable $ 175,000 $ (13,928 ) $ 161,072

Note 7 - Convertible Notes

Note 7 - Convertible Notes	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Convertible Debt [Text Block]	Note 7 March 2017 $2M In March 2017, third $1,000 6% 4,000 $0.25 4,000 $0.60 three March 2017 May 2017, $2,000,000. three 8,000,000 8,000,000 one $0.60 three $1,933,693, $904,690 $1,029,003 July 2017 $7.2M In July, 2017, third $1,000 6% 4,000 $0.25 4,000 $0.65 three July 2017 December 2017, $7,201,000. three 28,804,000 28,804,000 one $0.60 three $7,092,796, $3,142,605 3,950,191 As of March 31, 2020 $1,101,660, $155,340 March 2017 July 2017 $197,185. $409,589 March 31, 2020 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, $1,500,000 8% August 28, 2020 8,823,529 $0.17 100% The intrinsic value of the beneficial conversion feature resulting from the market price of the Company's common stock in excess of the conversion price was $176,471 On May 28, 2019, $170,000 8% February 28, 2019. 1,000,000 $0.17 17,225 $152,775. $1,330,000. On July 12, 2019, 8% $100,000 $100,000 July 12, 2019, $41,863 $0.11 We evaluated the modification under the guidance in ASC 470 50 10% $1,338,057, $133,806, $124,158. On August 1, 2019, 110,000 $0.11 1,000,000 $9,579 $100,421. 1,361,863. On October 23, 2019, October 23, 2019 $0.08 We evaluated the modification under the guidance in ASC 470 50 10% 2nd $1,269,067, $92,796, $92,796. On November 27, 2019, 8% “2nd 2nd $0.04 $30,000 We evaluated the modification under the guidance in ASC 470 50 2nd 10% 2nd no 2nd $1,361,863. On December 16, 2019, $120,000 $0.04 3,000,000 $57,551 $62,449. $1,271,863 $687,021, $584,842 During the year ended March 31, 2020 $398,591 $109,161 $289,430 March 31, 2020 862,382 $409,481. The Company is in default on the amended CSW Note due to non-payment of the quarterly interest payments due on October 1, 2019, January 1, 2020, March 1, 2020, March 31, 2018 5 ten 16 8% April 23, 2019 On April 23, 2019, 8% $2,765,000. $265,000 $0.17 April 22, 2020. A total discount of $440,000 $265,000 $175,000 year ended March 31, 2020 $617,430, $410,169 During the year ended March 31, 2020 $125,000 October 30, 2019, $75,000 $0.06 1,250,000 $64,706, November 18, 2019, $50,000 $0.0375 1,333,333 $62,353, $127,059 two year ended March 31, 2020 On April 22, 2020, 10% $286,059 June 30, 2020, $3,234,149. On May 20, 2020, not July 14, 2020, $3,264,594 15% not

Note 8 - Property and Equipment

Note 8 - Property and Equipment	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 8 Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of the asset or, in the case of leasehold improvements amortized over the lesser of the useful life of the asset or the underlying lease term. We recorded depreciation expense of $541,462 $338,190 year ended March 31, 2020 2019 $811,508 $584,017. $291,274 $126,447 year ended March 31, 2020 2019 March 31, 2020 2019 Furniture and fixtures $ - $ 20,883 Computer and software 151,748 151,748 Machinery and equipment 911,343 1,415,494 Leaseholds 3,367,591 5,120,758 Construction in progress 173,695 1,852,838 Capital lease - building 1,663,013 3,900,000 6,267,390 12,461,721 Less accumulated depreciation and amortization (733,557 ) (1,980,015 ) Property and Equipment, Net $ 5,533,833 $ 10,481,706 During the year ended March 31, 2020 100% 16 not $8.0 $11.9 $7.3 4,645,054 3 820. 17%.

Note 9 - Income Taxes

Note 9 - Income Taxes	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 9 The Company files income tax returns in the U.S. federal jurisdiction. The Company operates in the state of Nevada which does not The Company's effective tax rate was 0.0% - 2.4% March 31, 2020 2019 Income tax expense was $86,837 March 31, 2020 $38,913 $47,924 $506,145 March 31, 2018 March 31, 2020 $592,982 $506,145 March 31, 2018 $20,000 March 31, 2019 $86,837 $526,145 March 31, 2019 $510,647 $15,498 March 31, 2018 $506,145 March 31, 2019 At March 31, 2020 2019 $50,596,940 $47,430,184. 34,481,122 2025 2039. $16,115,818 March 31, 2019 no may 50% Because the Company operates in the legal cannabis industry, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. The provision for income taxes is different than would result from applying the U.S. statutory rate to profit before taxes for the reasons set forth in the following reconciliation: 2020 2019 Tax benefit computed at U.S. statutory rates $ (2,178,478 ) $ (4,424,959 ) Increases (decreases) in taxes resulting from: IRC Section 280E 202,877 968,870 Other permanent items 22,948 35,590 Change in valuation allowance 1,952,653 3,420,499 Prior year tax expense - 510,647 Total provision for income taxes $ - $ 510,647 The tax effects of the primary temporary differences giving rise to the Company's deferred tax assets and liabilities are as follows for the year ended March 31, 2020 2019 2020 2019 Deferred tax assets: Stock based compensation $ 2,943,816 $ 2,883,491 Net operating loss carryforward 10,625,357 9,960,339 Impairment of long-lived assets 975,461 - Depreciation and Amortization expense (324,707 ) (416,944 ) Other temporary items 136,243 68,520 Total deferred tax assets 14,356,170 12,495,406 Less valuation allowance (14,356,170 ) (12,495,406 ) Net deferred tax asset $ - $ - Deferred tax assets are evaluated by considering historical levels of income, estimates of future taxable income and the impact of tax planning strategies. The Company continues to evaluate its deferred tax asset valuation allowance on a quarterly basis. The Company concluded that, as of March 31, 2020 not not The Company believes that the tax positions taken in its tax returns would be sustained upon examination by taxing authorities. The Company files income tax returns in the U.S. federal jurisdiction and other required state jurisdictions. The Company's periodic tax returns filed in 2017

Note 10 - Capital Transactions

Note 10 - Capital Transactions	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 10 Increase in Authorized Capital Effective April 8, 2018, 250,000,000 400,000,000. August 15, 2019, 400,000,000 600,000,000. Year Ended March 31, 2020 Stock Issued for Debt Conversions During the year ended March 31, 2020 7,583,333 On May 28, 2019, $170,000 8% February 28, 2019 ( 6 1,000,000 $0.17 $17,225 $152,775. On August 1, 2019, $110,000 $0.11 1,000,000 $9,579 $100,421. $1,361,863. On December 16, 2019, $120,000 $0.04 3,000,000 $57,551 $62,449. $1,271,863 $687,021, $584,842 During the year ended March 31, 2020 $125,000 October 30, 2019, $75,000 $0.06 1,250,000 $64,706, November 18, 2019, $50,000 $0.0375 1,333,333 $62,353, $127,059 two year ended March 31, 2020 Exercise of Warrants for Stock During the year ended March 31, 2020 17,563,000 In order to encourage the exercise of approximately 70.5 $0.65 $0.30, $0.10 July 11, 2019. July 12, 2019, August 30, 2019, July 31, 2019, December 31, 2019. 9,449,750 $850,478, $94,498. $230,025. In order to encourage the further exercise of the warrants, the Company effected a temporary decrease in the exercise price of the warrants to $0.03 $.05 December 2019. 8,113,250 $307,249, $22,566. $32,215. Issuance of Stock for Services During the year ended March 31, 2020 2,100,000 214,000 Issuance of Stock and warrants for Cash During the year ended March 31, 2020 7,668,167 On December 4, 2018, 15,000,000 $0.20 $3 one one one $0.60 five January 15, 2019, $0.20 $0.15 20,000,000 $0.60 $0.30, no year ended March 31, 2020 $478,696 $71,529 3,668,167 3,668,167 one $0.30 During the year ended March 31, 2020 1,954,613 December 4, 2018 $0.30 five 132,914 year ended March 31, 2020 On October 10, 2019, 4,000,000 2,000,000 one $0.08 three $240,000 $110,000 Year Ended March 31, 2019 Stock Issued for Debt Conversions During the year ended March 31, 2019, $4,470,000 $170,971 Accordingly, the Company has issued 18,563,885 $0.25 $3,464,187 $1,005,813. Exercise of Warrants for Stock During the year ended March 31, 2019, 12,657,875 In order to encourage the exercise of the 8,000,000 March 2017 28,804,000 July 2017, $0.60 $0.65, $0.30 $0.325 12,332,750 $3.9 $2.9 The Company issued 325,125 $0.01 Issuance of Stock for Services The Company issued 4,032,407 $0.9 $0.3 Issuance of Stock for Cash During the year ended March 31, 2019, 277,778 $0.36 Stock Issued in Private Placement The Company issued 35,878,302 On August 10, 2018, 10,000,000 $0.25 one one one $0.60 three August 23, 2018, 10,000,000 20,000,000 no August 10, 2018 September 25, 2018, $4.4 $0.6 20 20 one three On December 4, 2018, 15,000,000 $0.20 $3 one one one $0.60 five January 15, 2019, $0.20 $0.15 20,000,000 $0.60 $0.30, no December 4, 2018 March 31, 2019, $2,072,125 $309,620 15,878,302 15,878,302 one $0.30 Issuance of Stock to Settle Pacific Leaf Royalty Agreement In connection with the Pacific Leaf Amendment and Termination Agreement, the Company issued 600,000 $131,000 Options and Warrants On December 1, 2018, 8 $0.1125 $969,197 March 31, 2019, $969,197 March 31, 2019. On December 6, 2018, 2 $0.1125 $244,000 twelve $81,333 March 31, 2019. In connection with the agreement with SylvaCap Media, the Company also agreed to pay a $10,000 12 4 2 June 6, 2019, December 6, 2018 $135,000 one not 2 In connection with the Placement Agent's Agreement dated August 10, 2018 August 23, 2018, 2,000,000 592,638 one $0.60 October 1, 2023. During the year ended March 31, 2019, 400,000 2014 10 $0.37 $0.60 $806,282 March 31, 2019. Warrants Outstanding Presented below is a summary of the Company's warrant activity for the years ended March 31, 2020 2019 Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2018 65,883,062 Warrants issued 47,878,302 0.30 0.60 Warrants exercised (12,657,875) 0.30 0.325 Warrants expired/cancelled (1,312,500) 0.50 2.00 Outstanding at March 31, 2019 99,790,989 Warrants issued 7,622,780 $0.30 Warrants exercised (17,563,000) 0.035 0.10 Warrants expired/cancelled (5,312,608) 0.50 2.00 Outstanding at March 31, 2020 84,538,161

Note 11 - Employee Benefit Plan

Note 11 - Employee Benefit Plan	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 11 In June 2018, 2018 07, 718 2018 07” No 2018 07 718 718 December 15, 2018, April 1, 2019. no Share-Based Employee Compensation On February 6, 2008, 2007 “2007 2007 4,500,000 may 2014 June 30, 2015, 8 8,500,000 April 6, 2018, 2014 2018 October 25, 2018, 8 10,000,000 2018 9,450,333 March 31, 2020. Compensation Expense For the years ended March 31, 2020 2019 $103,472 $806,282, no no March 31, 2020 Fair Value The closing price of the Company's stock on the date of grant is used as the fair value for issuances of restricted stock. The fair value of stock options granted is estimated as of the grant date using the Black-Scholes option pricing model. No year ended March 31, 2020 Year Ended March 31, 2020 March 31, 2019 Weighted-average volatility N/A 181.00 % Expected term (in years) N/A 10 Risk-free interest rate N/A 2.74 % Expected volatilities used for award valuation in 2019 The risk-free interest rate for periods equal to the expected term of an award is based on a blended historical rate using Federal Reserve rates for U.S. Treasury securities. Stock Options A summary of option activity as of March 31, 2020 2019 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Options Price $ Life (years) Value ($) Outstanding at April 1, 2018 13,033,334 $ 0.28 8.21 $ 2,646,723 Granted (Note 10) 400,000 $ 0.41 Exercised - $ - Forfeited (850,000 ) $ 0.24 Outstanding at March 31, 2019 12,583,334 $ 0.28 7.18 $ 43,000 Granted - Exercised - Forfeited (1,600,000 ) $ 0.27 Outstanding at March 31, 2020 10,983,334 $ 0.28 6.02 $ - Fully vested and expected to vest at March 31, 2020 10,983,334 $ 0.28 Exercisable at March 31, 2020 10,983,334 $ 0.28 Restricted stock awards No March 31, 2020 2019

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 12 On September 18, 2017 five two five The contract includes the Company's commitment to make an annual research investments of $500,000 50% 15 $250,000 $500,000 three $750,000. September one The monetary contributions will be used to conduct research on plant varieties, compounds, extraction techniques and delivery methods that could generate additional revenue through discoveries that are subject to intellectual property rights, of which AgCenter would retain 50% 50% 25% Tara “Dee” Russell filed a Charge of Discrimination with the Nevada Equal Rights Commission ("NERC") against the Company on April 2, 2019, May 15, 2019. July 26, 2019. not not On April 22, 2020, 7 10% $286,059 June 30, 2020, $3,234,149. On May 20, 2020, not July 14, 2020, $3,264,594 15% not On April 22, 2020, $73,050 $73,050 March 31, 2020. On December 6, 2018, 2 $0.1125 $244,000 $162,667 nine December 31, 2019. $10,000 12 4 2 2 nine On June 6, 2019, December 6, 2018 $135,000 one not two million March 31, 2020. On October 1, 2019, 2 $50,000 December 1, 2019, 2 90, 180, 270 $180,000 March 31, 2020. No no During the year ended March 31, 2019, $200,000 one not not September 6, 2019, From time to time, the Company may not

Note 13 - Deposits and Noncurre

Note 13 - Deposits and Noncurrent Assets	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Deposits and Prepayments [Text Block]	Note 13 Deposits and noncurrent assets were $ 91,504 230,651 March 31, 2020 2019 $91,600 year ended March 31, 2020 March 31, 2020

Note 14 - Related Party Transac

Note 14 - Related Party Transactions	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 14 As of March 31, 2020 586,512 $298,450 $76,183 $80,747 $131,132 In connection with the sale of membership interest in GB Sciences Louisiana, LLC, the Company issued a note payable in the amount of $151,923 first 15 March 31, 2020 During the year ended March 31, 2017, one year ended March 31, 2019 $1.1 During the year ended March 31, 2017, one one March 31, 2018. year ended March 31, 2019 $153,329 432,407 $122,363. January 29, 2019, February 28, 2019. On November 1, 2017, 20% 25% no Contemporaneously with the EPA, the Company entered into a Non-Revolving Credit Line Agreement and Non-Revolving Credit Line Promissory Note (together, the “THC Note” or “Note”) to advance up to $300,000 90 first 25% As of October 19, 2018, $253,034 October 19, 2018 October 22, 2018, The Company assessed the fair value of the machinery and equipment received at $139,411 year ended March 31, 2019 $113,623 year ended March 31, 2019

Note 15 - Sale of 50% Membershi

Note 15 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC	12 Months Ended
	Mar. 31, 2020
GB Sciences Louisiana, LLC, Sale of Equity [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 15 50% On February 12, 2018, 15% $3 35% 5% $1 $7.0 49.99%. On November 15, 2019, 50.01% $8,000,000 may $8,000,000 The Wellcana note bears interest at a rate of 5% June 1, 2020, December 1, 2021. $1,389,408 17.0%, $6,610,592 November 15, 2019: November 15, 2019 Note Receivable Note Payments June 1, 2020 $ 500,000 September 1, 2020 750,000 December 1, 2020 1,000,000 March 1, 2020 1,250,000 June 1, 2021 1,500,000 September 1, 2021 1,500,000 December 1, 2021 1,500,000 TOTAL PAYMENTS 8,000,000 DISCOUNT ON NOTE RECEIVABLE (1,389,408 ) NET PRESENT VALUE $ 6,610,592 Upon close of the sale on November 15, 2019, 4,393,242 As of Gain on Deconsolidation November 15, 2019 Present value of promissory note $ 6,610,592 Carrying amount of non-controlling interest 8,707,651 TOTAL 15,318,243 Carrying amount of assets 14,715,798 Carrying amount of liabilities (3,790,797 ) Net assets deconsolidated 10,925,001 GAIN ON DECONSOLIDATION $ 4,393,242 On August 24, 2020, $5,224,423, $324,423 $4,900,000 October 15, 2020, $8,000,000 $250,000 12 no $750,000 September 1, 2020 $500,000. $4,900,000 $8,000,000 As a result of the August 24, 2020 March 31, 2020 $5,224,423 August 24, 2020 Modification March 31, 2020 Total cash payments to be made by October 15, 2020 $ 4,900,000 Liabilities to be forgiven upon receipt of October 15, 2020 payment 324,423 Total receivable (as modified) 5,224,423 Carrying value of note receivable as of March 31, 2020 6,969,720 Accrued interest as of March 31, 2020 150,137 Total amount receivable as of March 31, 2020 7,119,857 LOSS ON MODIFICATION OF NOTE RECEIVABLE $ (1,895,434 ) The Company granted forbearance of the $500,000 June 1, 2020 19 August 4, 2020, $250,000 12 14 $189,423 The Company may $8,000,000 25% September 30, 2022, 10% 1 2 no October 15, 2020 $4,900,000, August 24, 2020 no For all periods presented in the consolidated financial statements, the assets, liabilities, income, and cash flows of GBSLA have been reclassified to discontinued operations. The losses and cash flows from discontinued operations for the year ended March 31, 2020 November 15, 2019.

Note 16 - Sale of 100% Membersh

Note 16 - Sale of 100% Membership Interest in Teco Facility and Nopah License	12 Months Ended
	Mar. 31, 2020
Nevada Subsidiaries [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 16 100% On November 15, 2019, 75% $3.0 $3.0 $470,000 6 8% 7 On March 24, 2020, 100% $4.0 $4.0 8% 36 The sale is expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevada has been subject to an indefinite moratorium since October 2019. July 21, 2020, 90 19 The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company's wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not November 27, 2019, 100% $300,000

Note 17 - Concentrations

Note 17 - Concentrations	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 17 For the year ended March 31, 2020 two 12.2% 13.8% Three 29.6%, 28.5%, 16.9% no March 31, 2020. $3,689,697 March 31, 2020, $3,120,620 85% $569,077 15%

Note 18 - Subsequent Events

Note 18 - Subsequent Events	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	Note 18 Capital Transactions March 31, 2020, 4,991,084 $0.03 $0.035 10 $136,082 $15,120 On May 7, 2020, $135,000 $15,000 $150,000 8.0% first $8 15 16 8,002,500 $0.04. $272,085 $49,525 $222,560. $150,000. On July 24, 2020, 8% "July 24 $500,000 may 7 July 24 $4.0 16 3 July 24 not July 24 Litigation On April 22, 2020, 7 10% $286,059 June 30, 2020, $3,234,149. On May 20, 2020, not July 14, 2020, $3,264,594 15% not On April 22, 2020, $73,050 $73,050 March 31, 2020. Wellcana Note Receivable The Company granted forbearance of the June 1, 2020 15 19 August 4, 2020, $250,000 12 5 $189,423 On August 24, 2020, $5,224,423, $324,423 $4,900,000 October 15, 2020, $8,000,000 $250,000 12 no $750,000 September 1, 2020 $500,000. $4,900,000 $8,000,000 As a result of the August 24, 2020 March 31, 2020 $5,224,423 ( 1,895,434 year ended March 31, 2020

Note 19 - Formation of GBS Glob

Note 19 - Formation of GBS Global Biopharma, Inc.	12 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Formation of Subsidiary [Text Block]	Note 19 On September 21, 2018, March 15, 2019, $1,435,700. The assets transferred include all intellectual property and intangible assets owned by the Company, consisting primarily of patents in process and research contracts with universities and researchers. GBS Global Biopharma, Inc. also assumed $475,586 third $1,435,700. Because the transaction consisted of an intercompany transfer of assets between wholly owned subsidiaries of GB Sciences, Inc., the promissory note and any gain or loss resulting from the Asset Purchase Agreement have been eliminated from the Company's consolidated financial statements for the years ended March 31, 2020 2019

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. The subsidiaries of the Company are: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC ECRX, Inc. GB Sciences Texas, LLC GB Sciences Nopah, LLC GBS Global Biopharma, Inc. Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. The current and long-term capital lease obligations recorded in the consolidated balance sheet as of March 31, 2019 15 no
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The assets and liabilities associated with discontinued operations included in our consolidated balance sheets are as follows: Discontinued Operations – (continued) March 31, 2020 March 31, 2019 Continuing Discontinued Total Continuing Discontinued Total ASSETS CURRENT ASSETS Cash $ 151,766 $ - $ 151,766 $ 182,055 $ 45,703 $ 227,758 Accounts receivable, net 117,967 - 117,967 488,329 - 488,329 Inventory, net 1,445,839 - 1,445,839 1,533,792 602,714 2,136,506 Prepaid and other current assets 60,885 - 60,885 262,208 351,970 614,178 Note receivable 5,224,423 - 5,224,423 - - - TOTAL CURRENT ASSETS 7,000,880 - 7,000,880 2,466,384 1,000,387 3,466,771 Property and equipment, net 5,533,833 - 5,533,833 10,481,706 13,022,996 23,504,702 Intangible assets, net 1,699,966 - 1,699,966 1,818,802 - 1,818,802 Deposits and other noncurrent assets 91,504 - 91,504 230,651 1,002,376 1,233,027 Operating lease right-of-use assets, net 26,685 - 26,685 - - - TOTAL ASSETS $ 14,352,868 $ - $ 14,352,868 $ 14,997,543 $ 15,025,759 $ 30,023,302 LIABILITIES CURRENT LIABILITIES Accounts payable $ 2,559,914 $ - $ 2,559,914 $ 1,374,771 $ 1,695,985 $ 3,070,756 Accrued interest 397,652 - 397,652 142,112 - 142,112 Accrued expenses 888,012 - 888,012 244,931 76,415 321,346 Notes payable, net 5,534,728 - 5,534,728 2,229,812 300,000 2,529,812 Indebtedness to related parties 586,512 - 586,512 - - - Note payable to related party 151,923 151,923 - - Income tax payable 592,982 - 592,982 506,145 - 506,145 Operating lease obligations, current 7,265 - 7,265 - - - Finance lease obligations, current 166,769 - 166,769 80,132 61,877 142,009 TOTAL CURRENT LIABILITIES 10,885,757 - 10,885,757 4,577,903 2,134,277 6,712,180 Note payable, net - - - 161,072 161,072 Operating lease obligations, long term 22,515 - 22,515 - - Finance lease obligations, long term 3,533,090 - 3,533,090 3,646,540 2,347,511 5,994,051 TOTAL LIABILITIES $ 14,441,362 $ - $ 14,441,362 $ 8,385,515 $ 4,481,788 $ 12,867,303 The revenues and expenses associated with discontinued operations included in our consolidated statements of operations were as follows: For the Year Ended March 31, For the Year Ended March 31, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ 3,120,620 $ 569,077 $ 3,689,697 $ 3,454,552 $ - $ 3,454,552 Cost of goods sold (4,002,083 ) (574,544 ) (4,576,627 ) (3,246,097 ) - (3,246,097 ) Gross profit (loss) (881,463 ) (5,467 ) (886,930 ) 208,455 - 208,455 General and administrative expenses 6,483,513 1,292,613 7,776,126 13,399,524 2,403,259 15,802,783 Loss on impairment of long-lived assets 4,645,054 - 4,645,054 - - - LOSS FROM OPERATIONS (12,010,030 ) (1,298,080 ) (13,308,110 ) (13,191,069 ) (2,403,259 ) (15,594,328 ) OTHER INCOME/(EXPENSE) Interest expense, net (1,625,204 ) (178,140 ) (1,803,344 ) (4,940,090 ) (251,168 ) (5,191,258 ) Other expense (194,248 ) - (194,248 ) (3,368,556 ) - (3,368,556 ) Loss on extinguishment (216,954 ) - (216,954 ) - - - Loss on modification of note receivable (1,895,434 ) (1,895,434 ) Gain on deconsolidation of subsidiary 4,393,242 - 4,393,242 - - - TOTAL OTHER INCOME/(EXPENSE) 461,402 (178,140 ) 283,262 (8,308,646 ) (251,168 ) (8,559,814 ) NET LOSS BEFORE INCOME TAXES (11,548,628 ) (1,476,220 ) (13,024,848 ) (21,499,715 ) (2,654,427 ) (24,154,142 ) Income tax expense (86,837 ) - (86,837 ) (526,145 ) - (526,145 ) NET LOSS $ (11,635,465 ) $ (1,476,220 ) $ (13,111,685 ) $ (22,025,860 ) $ (2,654,427 ) $ (24,680,287 )
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value primarily due to the short-term nature of the instruments.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three no March 31, 2020
Accounts Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections. During the year ended March 31, 2020 $108,001 $63,630 $44,371
Inventory, Policy [Policy Text Block]	Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	Indefinite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also include the acquisition cost of a cannabis production license with an indefinite life. We amortize our finite-lived intangible assets over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. During the year ended March 31, 2020 100% 16 not $449,801 $1,021,067 $571,266.
Lessee, Leases [Policy Text Block]	Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and has lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3 8 not
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets Property and equipment comprise a significant portion of our total assets. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not During the year ended March 31, 2020 100% 16 not $8.0 $11.9 $7.3 4,645,054 3 820. 17%. $4.0 $4.0M
Debt, Policy [Policy Text Block]	Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, “Application of Issue No. 98 5 first 718 Compensation – Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company's only current revenue source is from sales of cannabis, a distinct physical good. Under ASC 606, may may one 606 not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2020 2019 $1,543,397 $458,790
Share-based Payment Arrangement [Policy Text Block]	Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100%
Earnings Per Share, Policy [Policy Text Block]	Loss per Share The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 158,404,020 128,608,852 March 31, 2020 2019 not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Recently Adopted Standards In June 2016, No. 2016 13, 326 2016 13" 326 326 326 2016 13 not not December 15, 2019, April 1, 2019. not In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, April 1, 2019. not All other newly issued accounting pronouncements but not not

Note 3 - Basis of Presentatio_2

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2020
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	Discontinued Operations – (continued) March 31, 2020 March 31, 2019 Continuing Discontinued Total Continuing Discontinued Total ASSETS CURRENT ASSETS Cash $ 151,766 $ - $ 151,766 $ 182,055 $ 45,703 $ 227,758 Accounts receivable, net 117,967 - 117,967 488,329 - 488,329 Inventory, net 1,445,839 - 1,445,839 1,533,792 602,714 2,136,506 Prepaid and other current assets 60,885 - 60,885 262,208 351,970 614,178 Note receivable 5,224,423 - 5,224,423 - - - TOTAL CURRENT ASSETS 7,000,880 - 7,000,880 2,466,384 1,000,387 3,466,771 Property and equipment, net 5,533,833 - 5,533,833 10,481,706 13,022,996 23,504,702 Intangible assets, net 1,699,966 - 1,699,966 1,818,802 - 1,818,802 Deposits and other noncurrent assets 91,504 - 91,504 230,651 1,002,376 1,233,027 Operating lease right-of-use assets, net 26,685 - 26,685 - - - TOTAL ASSETS $ 14,352,868 $ - $ 14,352,868 $ 14,997,543 $ 15,025,759 $ 30,023,302 LIABILITIES CURRENT LIABILITIES Accounts payable $ 2,559,914 $ - $ 2,559,914 $ 1,374,771 $ 1,695,985 $ 3,070,756 Accrued interest 397,652 - 397,652 142,112 - 142,112 Accrued expenses 888,012 - 888,012 244,931 76,415 321,346 Notes payable, net 5,534,728 - 5,534,728 2,229,812 300,000 2,529,812 Indebtedness to related parties 586,512 - 586,512 - - - Note payable to related party 151,923 - 151,923 - - - Income tax payable 592,982 - 592,982 506,145 - 506,145 Operating lease obligations, current 7,265 - 7,265 - - - Finance lease obligations, current 166,769 - 166,769 80,132 61,877 142,009 TOTAL CURRENT LIABILITIES 10,885,757 - 10,885,757 4,577,903 2,134,277 6,712,180 Note payable, net - - - 161,072 - 161,072 Operating lease obligations, long term 22,515 - 22,515 - - - Finance lease obligations, long term 3,533,090 - 3,533,090 3,646,540 2,347,511 5,994,051 TOTAL LIABILITIES $ 14,441,362 $ - $ 14,441,362 $ 8,385,515 $ 4,481,788 $ 12,867,303 For the Year Ended March 31, For the Year Ended March 31, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ 3,120,620 $ 569,077 $ 3,689,697 $ 3,454,552 $ - $ 3,454,552 Cost of goods sold (4,002,083 ) (574,544 ) (4,576,627 ) (3,246,097 ) - (3,246,097 ) Gross profit (loss) (881,463 ) (5,467 ) (886,930 ) 208,455 - 208,455 General and administrative expenses 6,483,513 1,292,613 7,776,126 13,399,524 2,403,259 15,802,783 Loss on impairment of long-lived assets 4,645,054 - 4,645,054 - - - LOSS FROM OPERATIONS (12,010,030 ) (1,298,080 ) (13,308,110 ) (13,191,069 ) (2,403,259 ) (15,594,328 ) OTHER INCOME/(EXPENSE) Interest expense, net (1,625,204 ) (178,140 ) (1,803,344 ) (4,940,090 ) (251,168 ) (5,191,258 ) Other expense (194,248 ) - (194,248 ) (3,368,556 ) - (3,368,556 ) Loss on extinguishment (216,954 ) - (216,954 ) - - - Loss on modification of note receivable (1,895,434 ) - (1,895,434 ) - - - Gain on deconsolidation of subsidiary 4,393,242 - 4,393,242 - - - TOTAL OTHER INCOME/(EXPENSE) 461,402 (178,140 ) 283,262 (8,308,646 ) (251,168 ) (8,559,814 ) NET LOSS BEFORE INCOME TAXES (11,548,628 ) (1,476,220 ) (13,024,848 ) (21,499,715 ) (2,654,427 ) (24,154,142 ) Income tax expense (86,837 ) - (86,837 ) (526,145 ) - (526,145 ) NET LOSS $ (11,635,465 ) $ (1,476,220 ) $ (13,111,685 ) $ (22,025,860 ) $ (2,654,427 ) $ (24,680,287 )

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	12 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2020 March 31, 2019 Raw materials $ 91,465 $ 440,414 Work in progress 1,166,511 676,341 Finished goods 466,319 579,604 Subtotal 1,724,295 1,696,359 Allowance to reduce inventory to NRV (278,456 ) (162,567 ) Total inventory, net $ 1,445,839 $ 1,533,792

Note 5 - Leases (Tables)

Note 5 - Leases (Tables)	12 Months Ended
	Mar. 31, 2020
Notes Tables
Operating and Finance Lease Liabilities, Maturity [Table Text Block]	Year Ending Operating March 31, Finance Leases Leases 2021 $ 581,763 $ 11,779 2022 544,296 11,779 2023 560,625 11,779 2024 577,444 3,927 2025 594,767 - Thereafter 3,781,101 - Total minimum lease payments 6,639,996 39,264 Less: Amount representing interest (2,940,137 ) (9,484 ) Present value of minimum lease payments 3,699,859 29,780 Less: Current maturities of capital lease obligations (166,769 ) (7,265 ) Long-term capital lease obligations $ 3,533,090 $ 22,515

Note 6 - Notes Payable and Li_2

Note 6 - Notes Payable and Line of Credit (Tables)	12 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Amounts Recorded in Other Expense [Table Text Block]	Amounts Recorded in Other Expense Year Ended Related to the Amendment and Termination Agreement March 31, 2019 Prepaid royalties recorded in February 2018 $ 1,530,000 Cash payments made in August 2018 1,000,000 Promissory note issued to Pacific Leaf, due on or before November 30, 2018 500,000 100,000 shares common stock issued to Pacific Leaf 36,000 Settlement of convertible note payable and related accrued interest (20,075 ) 500,000 shares common stock issued to Pacific Leaf on December 21, 2018 95,000 Total $ 3,140,925
Schedule of Debt [Table Text Block]	As of March 31, 2020 Short-Term Notes Payable Face Value Discount Carrying Value 6% Convertible promissory notes payable (Note 7) $ 1,257,000 $ (155,340 ) $ 1,101,660 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 7) 1,271,863 (409,481 ) 862,382 8% Convertible Promissory Note dated April 23, 2019 (Note 7) 2,765,000 (29,830 ) 2,735,170 0% Note Payable dated October 23, 2017 (Note 6) 369,445 (13,929 ) 355,516 8% Line of Credit dated November 27, 2019 (Note 6) 480,000 - 480,000 Total Short-Term Notes Payable $ 6,143,308 $ (608,580 ) $ 5,534,728 As of March 31, 2019 Short-Term Notes Payable Face Value Discount Carrying Value 6% Convertible promissory notes payable (Note 7) $ 1,257,000 $ (564,929 ) $ 692,071 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 7) 1,500,000 (169,134 ) 1,330,866 0% Note Payable dated October 23, 2017 (Note 6) 272,222 (65,347 ) 206,875 Total Short-Term Notes Payable $ 3,029,222 $ (799,410 ) $ 2,229,812 0% Note Payable dated December 20, 2018 (discontinued operations) $ 300,000 $ - $ 300,000 Long-Term Notes Payable 0% Note Payable dated October 23, 2017 (Note 6) $ 175,000 $ (13,928 ) $ 161,072 Total Long-Term Notes Payable $ 175,000 $ (13,928 ) $ 161,072

Note 8 - Property and Equipme_2

Note 8 - Property and Equipment (Tables)	12 Months Ended
	Mar. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, 2020 2019 Furniture and fixtures $ - $ 20,883 Computer and software 151,748 151,748 Machinery and equipment 911,343 1,415,494 Leaseholds 3,367,591 5,120,758 Construction in progress 173,695 1,852,838 Capital lease - building 1,663,013 3,900,000 6,267,390 12,461,721 Less accumulated depreciation and amortization (733,557 ) (1,980,015 ) Property and Equipment, Net $ 5,533,833 $ 10,481,706

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2020 2019 Tax benefit computed at U.S. statutory rates $ (2,178,478 ) $ (4,424,959 ) Increases (decreases) in taxes resulting from: IRC Section 280E 202,877 968,870 Other permanent items 22,948 35,590 Change in valuation allowance 1,952,653 3,420,499 Prior year tax expense - 510,647 Total provision for income taxes $ - $ 510,647
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2020 2019 Deferred tax assets: Stock based compensation $ 2,943,816 $ 2,883,491 Net operating loss carryforward 10,625,357 9,960,339 Impairment of long-lived assets 975,461 - Depreciation and Amortization expense (324,707 ) (416,944 ) Other temporary items 136,243 68,520 Total deferred tax assets 14,356,170 12,495,406 Less valuation allowance (14,356,170 ) (12,495,406 ) Net deferred tax asset $ - $ -

Note 10 - Capital Transactions

Note 10 - Capital Transactions (Tables)	12 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2018 65,883,062 Warrants issued 47,878,302 0.30 0.60 Warrants exercised (12,657,875) 0.30 0.325 Warrants expired/cancelled (1,312,500) 0.50 2.00 Outstanding at March 31, 2019 99,790,989 Warrants issued 7,622,780 $0.30 Warrants exercised (17,563,000) 0.035 0.10 Warrants expired/cancelled (5,312,608) 0.50 2.00 Outstanding at March 31, 2020 84,538,161

Note 11 - Employee Benefit Pl_2

Note 11 - Employee Benefit Plan (Tables)	12 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended March 31, 2020 March 31, 2019 Weighted-average volatility N/A 181.00 % Expected term (in years) N/A 10 Risk-free interest rate N/A 2.74 %
Schedule of Stock Options Roll Forward [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Options Price $ Life (years) Value ($) Outstanding at April 1, 2018 13,033,334 $ 0.28 8.21 $ 2,646,723 Granted (Note 10) 400,000 $ 0.41 Exercised - $ - Forfeited (850,000 ) $ 0.24 Outstanding at March 31, 2019 12,583,334 $ 0.28 7.18 $ 43,000 Granted - Exercised - Forfeited (1,600,000 ) $ 0.27 Outstanding at March 31, 2020 10,983,334 $ 0.28 6.02 $ - Fully vested and expected to vest at March 31, 2020 10,983,334 $ 0.28 Exercisable at March 31, 2020 10,983,334 $ 0.28

Note 15 - Sale of 50% Members_2

Note 15 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Tables)	12 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Note Receivable with Imputed Interest [Table Text Block]	November 15, 2019 Note Receivable Note Payments June 1, 2020 $ 500,000 September 1, 2020 750,000 December 1, 2020 1,000,000 March 1, 2020 1,250,000 June 1, 2021 1,500,000 September 1, 2021 1,500,000 December 1, 2021 1,500,000 TOTAL PAYMENTS 8,000,000 DISCOUNT ON NOTE RECEIVABLE (1,389,408 ) NET PRESENT VALUE $ 6,610,592
Schedule of Deconsolidation [Table Text Block]	As of Gain on Deconsolidation November 15, 2019 Present value of promissory note $ 6,610,592 Carrying amount of non-controlling interest 8,707,651 TOTAL 15,318,243 Carrying amount of assets 14,715,798 Carrying amount of liabilities (3,790,797 ) Net assets deconsolidated 10,925,001 GAIN ON DECONSOLIDATION $ 4,393,242
Schedule of Gain (Loss) on Notes Receivable Modification [Table Text Block]	August 24, 2020 Modification March 31, 2020 Total cash payments to be made by October 15, 2020 $ 4,900,000 Liabilities to be forgiven upon receipt of October 15, 2020 payment 324,423 Total receivable (as modified) 5,224,423 Carrying value of note receivable as of March 31, 2020 6,969,720 Accrued interest as of March 31, 2020 150,137 Total amount receivable as of March 31, 2020 7,119,857 LOSS ON MODIFICATION OF NOTE RECEIVABLE $ (1,895,434 )

Note 1 - Background and Basis_2

Note 1 - Background and Basis of Presentation (Details Textual) - USD ($)	Mar. 24, 2020	Nov. 27, 2019	Nov. 15, 2019	Feb. 12, 2018	Oct. 15, 2020	Oct. 15, 2020	Mar. 31, 2020	Mar. 31, 2020	Aug. 15, 2019	Mar. 31, 2019	Apr. 08, 2018	Apr. 07, 2018	Mar. 31, 2018
Common Stock, Shares Authorized (in shares)							600,000,000	600,000,000	600,000,000	600,000,000	400,000,000	250,000,000	250,000,000
Wellcana Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total			$ 750,000				$ 7,119,857	$ 7,119,857
Forecast [Member] | Wellcana Note [Member]
Notes Receivable, Consideration Received from Collection						$ 5,224,423
Notes Receivable, Received Consideration, Liabilties Forgiven					$ 324,423	324,423
Proceeds from Collection of Notes Receivable					$ 4,900,000	$ 4,900,000
GB Sciences Louisiana, LLC [Member]
Proceeds from Divestiture of Businesses			8,000,000
Earnout Payments			8,000,000
Financing Receivable, after Allowance for Credit Loss, Total			$ 8,000,000
Teco [Member]
Sale of Stock, Percentage of Ownership	100.00%						100.00%
Proceeds from Divestiture of Businesses	$ 4,000,000
Proceeds from Collection of Notes Receivable							$ 4,000,000
Financing Receivable, after Allowance for Credit Loss, Total	$ 4,000,000
Notes Receivable, Interest Rate	8.00%
Notes Receivable, Term of Monthly Installments (Month)	3 years
Teco [Member]
Sale of Stock, Percentage of Ownership		75.00%	75.00%
Sale of Stock, Consideration Received on Transaction		$ 3,000,000	$ 3,000,000
Sale of Stock, Additional Earn-out Payments		$ 3,000,000	$ 3,000,000
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership		100.00%
Sale of Stock, Consideration Received on Transaction		$ 300,000
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC, Sale of Equity [Member]
Sale of Stock, Percentage of Ownership			50.01%	15.00%
Sale of Stock, Consideration Received on Transaction				$ 3,000,000				$ 7,000,000

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Retained Earnings (Accumulated Deficit), Ending Balance	$ (97,387,205)	$ (84,743,836)
Working Capital Deficit	3,884,877	3,245,409
Net Cash Provided by (Used in) Operating Activities, Total	(4,479,713)	(9,855,895)
Cash Provided by (Used in) Operating Activities, Discontinued Operations	$ (1,244,720)	(1,271,177)
Discontinued Operations [Member]
Working Capital Deficit		$ 1,133,890

Note 3 - Basis of Presentatio_3

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	Mar. 24, 2020	Mar. 31, 2020	Mar. 31, 2019
Short-term Investments, Total		$ 0
Accounts Receivable, Credit Loss Expense (Reversal)		108,001	$ 5,849
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease), Total		63,630
Accounts Receivable, Allowance for Credit Loss, Writeoff		44,371
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down		4,645,054
Research and Development Expense, Total		$ 1,543,397	$ 458,790
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)		158,404,020	128,608,852
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)		8 years
Production License [Member]
Asset Impairment Charges, Total		$ 449,801
Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance		$ 571,266	$ 1,021,067
Teco [Member]
Sale of Stock, Percentage of Ownership	100.00%	100.00%
Disposal Group, Including Disconitnued Operation, Estimated Future Undiscounted Cash Flows	$ 8,000,000
Disposal Group, Including Discontinued Operation, Carrying Basis	11,900,000
Disposal Group, Including Disconitnued Operation, Fair Value Disclosure	7,300,000
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down	$ 4,645,054
Disposal Group, Including Discontinued Operation, Discount Rate	17.00%
Proceeds from Collection of Notes Receivable		$ 4,000,000

Note 3 - Basis of Presentatio_4

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Discontinued Operations (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash	$ 151,766	$ 182,055
Accounts receivable, net of allowance for doubtful accounts of $130,378 and $66,748 at March 31, 2020 and 2019, respectively	117,967	488,329
Inventory, net	1,445,839	1,533,792
Prepaid expenses and other current assets	60,885	262,208
Note receivable	5,224,423
TOTAL CURRENT ASSETS	7,000,880	3,466,771
Property and equipment, net	5,533,833	10,481,706
Intangible assets, net of accumulated amortization of $12,287 and $3,745 at March 31, 2020 and 2019, respectively	1,699,966	1,818,802
Deposits and other noncurrent assets	91,504	230,651
Operating lease right-of-use assets, net	26,685
TOTAL ASSETS	14,352,868	30,023,302
Accounts payable	2,559,914	1,374,771
Accrued interest	397,652	142,112
Accrued liabilities	888,012	244,931
Notes and convertible notes payable, net of unamortized discount of $608,580 and $799,410 at March 31, 2020 and 2019, respectively	5,534,728	2,229,812
Indebtedness to related parties	586,512
Note payable to related party	151,923
Income tax payable	592,982	506,145
Operating lease obligations, current	7,265
Finance lease obligations, current	166,769	80,132
TOTAL CURRENT LIABILITIES	10,885,757	6,712,180
Note payable, net of unamortized discount of $0 and $13,928 at March 31, 2020 and 2019, respectively		161,072
Operating lease obligations, long term	22,515
Finance lease obligations, long term	3,533,090	3,646,540
TOTAL LIABILITIES	14,441,362	12,867,303
Sales revenue	3,120,620	3,454,552
Cost of goods sold	(4,002,083)	(3,246,097)
Gross profit (loss)	(881,463)	208,455
General and administrative expenses	6,483,513	13,399,524
LOSS FROM OPERATIONS	(12,010,030)	(13,191,069)
Interest expense	(1,625,204)	(4,940,090)
Other expense	(194,248)	(3,368,556)
Loss on extinguishment	(216,954)
LOSS ON MODIFICATION OF NOTE RECEIVABLE	(1,895,434)
Gain on deconsolidation of subsidiary	4,393,242
TOTAL OTHER INCOME/(EXPENSE)	461,402	(8,308,646)
NET LOSS BEFORE INCOME TAXES	(11,548,628)	(21,499,715)
Income tax expense	(86,837)	(526,145)
Net loss	(13,111,685)	(24,680,287)
Continuing Operations [Member]
Cash	151,766	182,055
Accounts receivable, net of allowance for doubtful accounts of $130,378 and $66,748 at March 31, 2020 and 2019, respectively	117,967	488,329
Inventory, net	1,445,839	1,533,792
Prepaid expenses and other current assets	60,885	262,208
Note receivable	5,224,423
TOTAL CURRENT ASSETS	7,000,880	2,466,384
Property and equipment, net	5,533,833	10,481,706
Intangible assets, net of accumulated amortization of $12,287 and $3,745 at March 31, 2020 and 2019, respectively	1,699,966	1,818,802
Deposits and other noncurrent assets	91,504	230,651
Operating lease right-of-use assets, net	26,685
TOTAL ASSETS	14,352,868	14,997,543
Accounts payable	2,559,914	1,374,771
Accrued interest	397,652	142,112
Accrued liabilities	888,012	244,931
Notes and convertible notes payable, net of unamortized discount of $608,580 and $799,410 at March 31, 2020 and 2019, respectively	5,534,728	2,229,812
Indebtedness to related parties	586,512
Note payable to related party	151,923
Income tax payable	592,982	506,145
Operating lease obligations, current	7,265
Finance lease obligations, current	166,769	80,132
TOTAL CURRENT LIABILITIES	10,885,757	4,577,903
Note payable, net of unamortized discount of $0 and $13,928 at March 31, 2020 and 2019, respectively		161,072
Operating lease obligations, long term	22,515
Finance lease obligations, long term	3,533,090	3,646,540
TOTAL LIABILITIES	14,441,362	8,385,515
Sales revenue	3,120,620	3,454,552
Cost of goods sold	(4,002,083)	(3,246,097)
Gross profit (loss)	(881,463)	208,455
General and administrative expenses	6,483,513	13,399,524
Loss on impairment of long-lived assets	4,645,054
LOSS FROM OPERATIONS	(12,010,030)	(13,191,069)
Interest expense	(1,625,204)	(4,940,090)
Other expense	(194,248)	(3,368,556)
Loss on extinguishment	(216,954)
LOSS ON MODIFICATION OF NOTE RECEIVABLE	(1,895,434)
Gain on deconsolidation of subsidiary	4,393,242
TOTAL OTHER INCOME/(EXPENSE)	461,402	(8,308,646)
NET LOSS BEFORE INCOME TAXES	(11,548,628)	(21,499,715)
Income tax expense	(86,837)	(526,145)
Net loss	(11,635,465)	(22,025,860)
Discontinued Operations [Member]
Cash		45,703
Accounts receivable, net of allowance for doubtful accounts of $130,378 and $66,748 at March 31, 2020 and 2019, respectively
Inventory, net		602,714
Prepaid expenses and other current assets		351,970
Note receivable
TOTAL CURRENT ASSETS		1,000,387
Property and equipment, net		13,022,996
Intangible assets, net of accumulated amortization of $12,287 and $3,745 at March 31, 2020 and 2019, respectively
Deposits and other noncurrent assets		1,002,376
Operating lease right-of-use assets, net
TOTAL ASSETS		15,025,759
Accounts payable		1,695,985
Accrued interest
Accrued liabilities		76,415
Notes and convertible notes payable, net of unamortized discount of $608,580 and $799,410 at March 31, 2020 and 2019, respectively		300,000
Indebtedness to related parties
Note payable to related party
Income tax payable
Operating lease obligations, current
Finance lease obligations, current		61,877
TOTAL CURRENT LIABILITIES		2,134,277
Note payable, net of unamortized discount of $0 and $13,928 at March 31, 2020 and 2019, respectively
Operating lease obligations, long term
Finance lease obligations, long term		2,347,511
TOTAL LIABILITIES		4,481,788
Sales revenue	569,077
Cost of goods sold	(574,544)
Gross profit (loss)	(5,467)
General and administrative expenses	1,292,613	2,403,259
Loss on impairment of long-lived assets
LOSS FROM OPERATIONS	(1,298,080)	(2,403,259)
Interest expense	(178,140)	(251,168)
Other expense
Loss on extinguishment
LOSS ON MODIFICATION OF NOTE RECEIVABLE
Gain on deconsolidation of subsidiary
TOTAL OTHER INCOME/(EXPENSE)	(178,140)	(251,168)
NET LOSS BEFORE INCOME TAXES	(1,476,220)	(2,654,427)
Income tax expense
Net loss	(1,476,220)	(2,654,427)
Segment, Continuing and Discontinued Operations [Member]
Cash	151,766	227,758
Accounts receivable, net of allowance for doubtful accounts of $130,378 and $66,748 at March 31, 2020 and 2019, respectively	117,967	488,329
Inventory, net	1,445,839	2,136,506
Prepaid expenses and other current assets	60,885	614,178
Note receivable	5,224,423
TOTAL CURRENT ASSETS	7,000,880	3,466,771
Property and equipment, net	5,533,833	23,504,702
Intangible assets, net of accumulated amortization of $12,287 and $3,745 at March 31, 2020 and 2019, respectively	1,699,966	1,818,802
Deposits and other noncurrent assets	91,504	1,233,027
Operating lease right-of-use assets, net	26,685
TOTAL ASSETS	14,352,868	30,023,302
Accounts payable	2,559,914	3,070,756
Accrued interest	397,652	142,112
Accrued liabilities	888,012	321,346
Notes and convertible notes payable, net of unamortized discount of $608,580 and $799,410 at March 31, 2020 and 2019, respectively	5,534,728	2,529,812
Indebtedness to related parties	586,512
Note payable to related party	151,923
Income tax payable	592,982	506,145
Operating lease obligations, current	7,265
Finance lease obligations, current	166,769	142,009
TOTAL CURRENT LIABILITIES	10,885,757	6,712,180
Note payable, net of unamortized discount of $0 and $13,928 at March 31, 2020 and 2019, respectively		161,072
Operating lease obligations, long term	22,515
Finance lease obligations, long term	3,533,090	5,994,051
TOTAL LIABILITIES	14,441,362	12,867,303
Sales revenue	3,689,697	3,454,552
Cost of goods sold	(4,576,627)	(3,246,097)
Gross profit (loss)	(886,930)	208,455
General and administrative expenses	7,776,126	15,802,783
Loss on impairment of long-lived assets	4,645,054
LOSS FROM OPERATIONS	(13,308,110)	(15,594,328)
Interest expense	(1,803,344)	(5,191,258)
Other expense	(194,248)	(3,368,556)
Loss on extinguishment	(216,954)
LOSS ON MODIFICATION OF NOTE RECEIVABLE	(1,895,434)
Gain on deconsolidation of subsidiary	4,393,242
TOTAL OTHER INCOME/(EXPENSE)	283,262	(8,559,814)
NET LOSS BEFORE INCOME TAXES	(13,024,848)	(24,154,142)
Income tax expense	(86,837)	(526,145)
Net loss	$ (13,111,685)	$ (24,680,287)

Note 4 - Inventory - Schedule o

Note 4 - Inventory - Schedule of Inventory (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Raw materials	$ 91,465	$ 440,414
Work in progress	1,166,511	676,341
Finished goods	466,319	579,604
Subtotal	1,724,295	1,696,359
Allowance to reduce inventory to NRV	(278,456)	(162,567)
Total inventory, net	$ 1,445,839	$ 1,533,792

Note 5 - Leases (Details Textua

Note 5 - Leases (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2020	Apr. 01, 2019	Mar. 31, 2019
Operating Lease, Right-of-Use Asset	$ 26,685
Operating Lease, Liability, Total	$ 29,780
Lessee, Operating Lease, Discount Rate	17.00%
Finance Lease Costs	$ 679,347
Finance Lease, Interest Expense	426,374
Finance Lease, Right-of-Use Asset, Amortization	252,973
Operating Lease, Cost	75,306
Operating Lease, Interest Expense	27,611
Operating Lease, Right-of-Use Asset, Amortization Expense	47,695
Discontinued Operations [Member]
Operating Lease, Right-of-Use Asset
Finance Lease Costs	280,227
Finance Lease, Interest Expense	153,977
Finance Lease, Right-of-Use Asset, Amortization	$ 126,250
Minimum [Member]
Lessee, Finance Lease, Discount Rate	10.20%
Maximum [Member]
Lessee, Finance Lease, Discount Rate	11.50%
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset		$ 182,624
Operating Lease, Liability, Total		$ 190,173

Note 5 - Leases - Future Minimu

Note 5 - Leases - Future Minimum Lease Payments (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
2021, finance leases	$ 581,763
2021, operating leases	11,779
2022, finance leases	544,296
2022, operating leases	11,779
2023, finance leases	560,625
2023, operating leases	11,779
2024, finance leases	577,444
2024, operating leases	3,927
2025, finance leases	594,767
2025, operating leases
Thereafter, finance leases	3,781,101
Thereafter, operating leases
Total minimum lease payments, finance leases	6,639,996
Total minimum lease payments, operating leases	39,264
Less: Amount representing interest, finance leases	(2,940,137)
Less: Amount representing interest, operating leases	(9,484)
Present value of minimum lease payments, finance leases	3,699,859
Present value of minimum lease payments, operating leases	29,780
Less: Current maturities of capital lease obligations, finance leases	(166,769)	$ (80,132)
Less: Current maturities of capital lease obligations, operating leases	(7,265)
Finance lease obligations, long term	3,533,090	3,646,540
Operating lease obligations, long term	$ 22,515

Note 6 - Notes Payable and Li_3

Note 6 - Notes Payable and Line of Credit (Details Textual)

Nov. 15, 2019USD ($)

Mar. 04, 2019USD ($)

Feb. 06, 2019USD ($)

Jan. 16, 2019USD ($)

Dec. 21, 2018USD ($)shares

Dec. 20, 2018USD ($)

Jul. 31, 2018USD ($)shares

Jul. 28, 2018USD ($)

Oct. 23, 2017USD ($)

Aug. 31, 2018USD ($)

Feb. 28, 2018USD ($)

Sep. 30, 2018USD ($)

Nov. 15, 2019USD ($)

Mar. 31, 2020USD ($)

Mar. 31, 2019USD ($)shares

Nov. 27, 2019USD ($)

Nov. 30, 2018

Debt Instrument, Face Amount

$ 175,000

Stock Issued to Settle Royalty Agreement, Shares (in shares) | shares

600,000

Stock Issued to Settle Royalty Agreement, Value

$ 131,000

Interest Paid, Excluding Capitalized Interest, Operating Activities

451,040

539,242

Other Expenses, Total

3,140,925

Proceeds from Lines of Credit, Total

480,000

Line of Credit [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 470,000

Proceeds from Lines of Credit, Total

480,000

Line of Credit Facility, Maximum Borrowing Capacity, Increased

10,000

Interest Payable

10,444

Long-term Line of Credit, Total

480,000

Promissory Note [Member]

Debt Instrument, Face Amount

6,143,308

3,029,222

Other Expense [Member]

Repayments of Debt

$ 1,000,000

Royalty Expense

$ 1,530,000

Stock Issued to Settle Royalty Agreement, Shares (in shares) | shares

500,000

100,000

The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]

Debt Instrument, Debt Default, Remaining Balance

369,444

The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]

Debt Instrument, Face Amount

$ 700,000

Debt Instrument, Interest Rate, Stated Percentage

0.00%

Interest Expense, Debt, Total

53,122

Debt Instrument, Term (Year)

3 years

Debt Instrument, Present Value

$ 521,067

Receivable with Imputed Interest, Effective Yield (Interest Rate)

20.30%

Debt Instrument, Unamortized Discount, Total

$ 178,933

Debt Instrument, Accrued Monthly Payments, Amount

$ 291,660

Debt Instrument, Debt Default, Interest Rate Penalty

10.00%

Debt Instrument, Debt Default, Accrued Interest

$ 30,787

Days to Cure Breach of Default After Notification From Lender

10

Amendment and Termination Agreement [Member] | Pacific Leaf [Member]

Stock Issued to Settle Royalty Agreement, Shares (in shares) | shares

100,000

Stock Issued to Settle Royalty Agreement, Value

$ 36,000

Amendment and Termination Agreement [Member] | Pacific Leaf [Member] | Other Expense [Member]

Stock Issued to Settle Royalty Agreement, Value

$ 36,000

Nevada Medical Marijuana Production License Agreement [Member]

Payments to Acquire License

$ 500,000

Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member]

Ownership of Licence

100.00%

Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member]

Ownership of Licence

100.00%

Pacific Leaf [Member] | The 6% Note Payable Due November 30, 2018 [Member]

Debt Conversion, Original Debt, Amount

$ 500,000

Debt Instrument, Interest Rate, Stated Percentage

6.00%

Stock Issued to Settle Royalty Agreement, Shares (in shares) | shares

500,000

Repayments of Notes Payable

$ 210,000

$ 100,000

$ 100,000

$ 100,000

Interest Paid, Excluding Capitalized Interest, Operating Activities

12,164

Repayments of Notes Payable, Principal

$ 87,836

Other Expenses, Total

95,000

Interest Expense, Debt, Total

$ 15,929

Pacific Leaf [Member] | Amendment and Termination Agreement [Member]

Repayments of Debt

1,000,000

Debt Instrument, Face Amount

$ 1,500,000

Royalty Expense

$ 1,530,000

Pacific Leaf [Member] | Amendment and Termination Agreement [Member] | Other Expense [Member]

Repayments of Debt

$ 1,000,000

BCM MED [Member] | The 0% Note Payable Dated December 20, 2018 [Member] | Notes Payable, Other Payables [Member]

Repayments of Debt

$ 266,667

Debt Instrument, Face Amount

$ 300,000

Debt Instrument, Periodic Payments, Number of Monthly Payments

8

Debt Instrument, Periodic Payment, Total

$ 33,333

Debt Instrument, Increase (Decrease), Net, Total

$ 33,333

Note 6 - Notes Payable and Li_4

Note 6 - Notes Payable and Line of Credit - Amounts Recorded in Other Expense (Details) - USD ($)	Dec. 21, 2018	Jul. 31, 2018	Aug. 31, 2018	Feb. 28, 2018	Mar. 31, 2019
Total					$ 3,140,925
Other Expense [Member]
Prepaid royalties recorded in February 2018				$ 1,530,000
Cash payments made in August 2018			$ 1,000,000
Promissory note issued to Pacific Leaf, due on or before November 30, 2018					500,000
Shares common stock issued to Pacific Leaf	$ 95,000	$ 36,000
Settlement of convertible note payable and related accrued interest					$ (20,075)

Note 6 - Notes Payable and Li_5

Note 6 - Notes Payable and Line of Credit - Amounts Recorded in Other Expense (Details) (Parentheticals) - shares	Dec. 21, 2018	Jul. 31, 2018	Mar. 31, 2019
Stock Issued to Settle Royalty Agreement, Shares (in shares)			600,000
Other Expense [Member]
Stock Issued to Settle Royalty Agreement, Shares (in shares)	500,000	100,000

Note 6 - Notes Payable and Li_6

Note 6 - Notes Payable and Line of Credit - Schedule of Debt Payable (Details) - USD ($)	Mar. 31, 2020	Apr. 23, 2019	Mar. 31, 2019
Face Value, short-term notes payable			$ 175,000
Discount, short-term notes payable	$ (608,580)		(799,410)
Discount, long-term notes payable	0		(13,928)
Carrying Value, long-term notes payable			161,072
The 0% Note Payable Dated October 23, 2017 [Member]
Face Value, short-term notes payable			175,000
Discount, long-term notes payable			(13,928)
Carrying Value, long-term notes payable			161,072
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member]
Face Value, short-term notes payable	1,257,000		1,257,000
Discount, short-term notes payable	(155,340)		(564,929)
Carrying Value, short-term notes payable	1,101,660		692,071
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Face Value, short-term notes payable	2,765,000	$ 2,765,000
Discount, short-term notes payable	(29,830)
Carrying Value, short-term notes payable	2,735,170
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Face Value, short-term notes payable	369,445		272,222
Discount, short-term notes payable	(13,929)		(65,347)
Carrying Value, short-term notes payable	355,516		206,875
Senior Secured Convertible Promissory Note [Member] | The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Face Value, short-term notes payable	1,271,863		1,500,000
Discount, short-term notes payable	(409,481)		(169,134)
Carrying Value, short-term notes payable	862,382		1,330,866
Promissory Note [Member]
Face Value, short-term notes payable	6,143,308		3,029,222
Discount, short-term notes payable	(608,580)		(799,410)
Carrying Value, short-term notes payable	5,534,728		2,229,812
Line of Credit [Member]
Face Value, short-term notes payable	480,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	$ 480,000
The 0% Note Payable Dated December 20, 2018 [Member] | Discontinued Operations [Member]
Face Value, short-term notes payable			300,000
Discount, short-term notes payable
Carrying Value, short-term notes payable			$ 300,000

Note 7 - Convertible Notes (Det

Note 7 - Convertible Notes (Details Textual)	Jul. 14, 2020USD ($)	Apr. 22, 2020USD ($)	Dec. 16, 2019USD ($)$ / sharesshares	Nov. 27, 2019USD ($)$ / shares	Nov. 18, 2019USD ($)$ / sharesshares	Oct. 30, 2019USD ($)$ / sharesshares	Oct. 23, 2019USD ($)$ / shares	Aug. 01, 2019USD ($)$ / sharesshares	Jul. 12, 2019USD ($)$ / shares	May 28, 2019USD ($)$ / sharesshares	Apr. 23, 2019USD ($)$ / shares	Feb. 28, 2019USD ($)$ / shares	Jul. 31, 2017USD ($)$ / shares	Mar. 31, 2017USD ($)$ / shares	May 31, 2017USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2020USD ($)shares	Mar. 30, 2020USD ($)	Mar. 31, 2019USD ($)$ / shares	Jun. 30, 2020USD ($)	Dec. 31, 2019USD ($)
Debt Instrument, Face Amount																			$ 175,000
Interest Payable, Current																	$ 397,652		142,112
Amortization of Debt Discount (Premium)																	$ 1,150,995		793,820
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares																	7,583,333
Gain (Loss) on Extinguishment of Debt, Total																	$ (216,954)
Interest Expense, Debt, Excluding Amortization																	84,354		3,464,187
Induced Conversion of Convertible Debt Expense																	127,059
Subsequent Event [Member] | Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Debt Instrument, Debt Default, Interest Rate Penalty	15.00%
Litigation Settlement, Amount Awarded to Other Party	$ 3,264,594
Warrants Issued in March 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants														4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares														$ 0.60	$ 0.60				$ 0.30
Warrants and Rights Outstanding, Term (Year)														3 years	3 years
Class of Warrant or Right, Issued (in shares) | shares															8,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares															1
Warrants Related to July 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants													4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares													$ 0.65			$ 0.60			$ 0.325
Warrants and Rights Outstanding, Term (Year)																3 years
Class of Warrant or Right, Issued (in shares) | shares																28,804,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares																1
Convertible Notes Payable [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature																	829,737		$ 176,471
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note														$ 1,000
Debt Instrument, Interest Rate, Stated Percentage														6.00%
Debt Instrument, Face Amount															$ 2,000,000
Debt Instrument, Term (Year)															3 years
Debt Instrument, Unamortized Discount, Total															$ 1,933,693
Debt Instrument, Convertible, Beneficial Conversion Feature															904,690
Debt Instrument, Convertible, Discount, Fair Value of Warrants															$ 1,029,003
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments														4,000	8,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares														$ 0.25
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note													$ 1,000
Debt Instrument, Face Amount																$ 7,201,000
Debt Instrument, Term (Year)													3 years			3 years
Debt Instrument, Unamortized Discount, Total																$ 7,092,796
Debt Instrument, Convertible, Beneficial Conversion Feature																3,142,605
Debt Instrument, Convertible, Discount, Fair Value of Warrants																$ 3,950,191
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments													4,000			28,804,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares													$ 0.25
Convertible Notes Payable [Member] | March 2017 and July 2017 Note Offerings [Member]
Debt Instrument, Unamortized Discount, Total																		$ 155,340
Long-term Debt, Gross																		1,101,660
Interest Payable, Current																		197,185
Amortization of Debt Discount (Premium)																		$ 409,589
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage											8.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares					$ 0.0375	$ 0.06					$ 0.17
Debt Instrument, Face Amount											$ 2,765,000						2,765,000
Debt Instrument, Unamortized Discount, Total											265,000
Amortization of Debt Discount (Premium)																	410,169
Debt Conversion, Original Debt, Amount					$ 50,000	$ 75,000											125,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares					1,333,333	1,250,000
Short-term Debt, Total																	2,735,170
Interest Expense, Debt, Total																	617,430
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total											440,000
Payments for Brokerage Fees											$ 175,000
Induced Conversion of Convertible Debt Expense					$ 62,353	$ 64,706											127,059
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Subsequent Event [Member]
Long-term Debt, Gross																				$ 3,234,149
Debt Instrument, Debt Default, Interest Rate Penalty		10.00%
Debt Instrument, Default, Expense		$ 286,059
Promissory Note [Member]
Debt Instrument, Face Amount																	6,143,308		3,029,222
Short-term Debt, Total																	$ 5,534,728		$ 2,229,812
Promissory Note [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Interest Rate, Stated Percentage													6.00%
Senior Secured Convertible Promissory Note [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares																			$ 0.25
Debt Instrument, Unamortized Discount, Total																			$ 3,464,187
Debt Instrument, Increase (Decrease), Net, Total																			(1,005,813)
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage									8.00%	8.00%		8.00%
Debt Instrument, Face Amount												$ 1,500,000
Debt Instrument, Unamortized Discount, Total			$ 57,551					$ 9,579		$ 17,225											$ 584,842
Debt Instrument, Convertible, Beneficial Conversion Feature							$ 92,796		$ 133,806			$ 176,471
Debt Conversion, Original Debt, Amount			120,000					110,000		170,000
Debt Instrument, Increase (Decrease), Net, Total			(62,449)	$ 30,000				(100,421)	100,000	(152,775)
Short-term Debt, Total			$ 1,271,863	1,361,863			1,269,067	$ 1,361,863	1,338,057	$ 1,330,000											$ 687,021
Proceeds from Related Party Debt									100,000
Debt Instrument, Increase, Accrued Interest									41,863
Gain (Loss) on Extinguishment of Debt, Total				$ 0			$ (92,796)		$ (124,158)
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Minimum [Member]
Days to Cure Breach of Default After Notification From Lender																	5
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Maximum [Member]
Days to Cure Breach of Default After Notification From Lender																	10
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | GB Sciences, Nevada, LLC [Member] | Collateral Pledged [Member]
Noncontrolling Interest, Ownership Percentage by Parent												100.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments												8,823,529
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 0.04	$ 0.04			$ 0.08	$ 0.11	$ 0.11	$ 0.17		$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares			3,000,000					1,000,000		1,000,000
Senior Secured Convertible Promissory Note [Member] | The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Instrument, Face Amount																	$ 1,271,863		1,500,000
Debt Instrument, Unamortized Discount, Total																	409,481
Long-term Debt, Gross																	862,382
Amortization of Debt Discount (Premium)																	289,430
Short-term Debt, Total																	862,382		$ 1,330,866
Interest Expense, Debt, Total																	398,591
Interest Expense, Debt, Excluding Amortization																	$ 109,161

Note 8 - Property and Equipme_3

Note 8 - Property and Equipment (Details Textual) - USD ($)	Mar. 24, 2020	Mar. 31, 2020	Mar. 31, 2019
Depreciation, Total		$ 541,462	$ 338,190
Depreciation, Capitalized to Inventory		811,508	584,017
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down		$ 4,645,054
Teco [Member]
Sale of Stock, Percentage of Ownership	100.00%	100.00%
Disposal Group, Including Disconitnued Operation, Estimated Future Undiscounted Cash Flows	$ 8,000,000
Disposal Group, Including Discontinued Operation, Carrying Basis	11,900,000
Disposal Group, Including Disconitnued Operation, Fair Value Disclosure	7,300,000
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down	$ 4,645,054
Disposal Group, Including Discontinued Operation, Discount Rate	17.00%
Discontinued Operations [Member]
Depreciation, Total		$ 291,274	$ 126,447

Note 8 - Property and Equipme_4

Note 8 - Property and Equipment - Property and Equipment (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Property and Equipment, Gross	$ 6,267,390	$ 12,461,721
Less accumulated depreciation and amortization	(733,557)	(1,980,015)
Property and Equipment, Net	5,533,833	10,481,706
Furniture and Fixtures [Member]
Property and Equipment, Gross		20,883
Computer Equipment [Member]
Property and Equipment, Gross	151,748	151,748
Machinery and Equipment [Member]
Property and Equipment, Gross	911,343	1,415,494
Leaseholds and Leasehold Improvements [Member]
Property and Equipment, Gross	3,367,591	5,120,758
Construction in Progress [Member]
Property and Equipment, Gross	173,695	1,852,838
Capital Lease, Building [Member]
Property and Equipment, Gross	$ 1,663,013	$ 3,900,000

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	(2.40%)
Income Tax Expense (Benefit), Total	$ 86,837	$ 526,145
Income Tax Reconciliation, Prior Year Tax Penalties	38,913	15,498
Income Tax Reconciliation, Accrued Interest on Prior Year Tax Liabilities	47,924
Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount	506,145	510,647
Taxes Payable, Current, Total	592,982	506,145
Income Taxes Paid		20,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total			$ 86,837
Operating Loss Carryforwards, Total	50,596,940	$ 47,430,184
Operating Loss Carryforwards, Subject to Expiration	34,481,122
Operating Loss Carryforwards, Not Subject to Expiration	$ 16,115,818

Note 9 - Income Taxes - Reconci

Note 9 - Income Taxes - Reconciliation of Effective Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Tax benefit computed at U.S. statutory rates	$ (2,178,478)	$ (4,424,959)
IRC Section 280E	202,877	968,870
Other permanent items	22,948	35,590
Change in valuation allowance	1,952,653	3,420,499
Prior year tax expense		510,647
Total provision for income taxes		$ 510,647

Note 9 - Income Taxes - Deferre

Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Stock based compensation	$ 2,943,816	$ 2,883,491
Net operating loss carryforward	10,625,357	9,960,339
Impairment of long-lived assets	975,461
Depreciation and Amortization expense	(324,707)	(416,944)
Other temporary items	136,243	68,520
Total deferred tax assets	14,356,170	12,495,406
Less valuation allowance	(14,356,170)	(12,495,406)
Net deferred tax asset

Note 10 - Capital Transaction_2

Note 10 - Capital Transactions (Details Textual)	Dec. 16, 2019USD ($)$ / sharesshares	Nov. 27, 2019USD ($)$ / shares	Nov. 18, 2019USD ($)$ / sharesshares	Oct. 30, 2019USD ($)$ / sharesshares	Oct. 10, 2019USD ($)$ / sharesshares	Oct. 01, 2019USD ($)shares	Aug. 01, 2019USD ($)$ / sharesshares	Jul. 12, 2019USD ($)$ / sharesshares	Jun. 06, 2019USD ($)shares	May 28, 2019USD ($)$ / sharesshares	Dec. 06, 2018USD ($)$ / sharesshares	Aug. 23, 2018$ / sharesshares	Aug. 10, 2018USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Sep. 25, 2018USD ($)shares	Jul. 11, 2019$ / sharesshares	May 31, 2017$ / sharesshares	Mar. 31, 2019USD ($)$ / sharesshares	Jun. 06, 2019shares	Dec. 31, 2017$ / sharesshares	Dec. 31, 2019USD ($)$ / shares	Mar. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2019USD ($)$ / sharesshares	Oct. 23, 2019USD ($)$ / shares	Aug. 15, 2019shares	Apr. 23, 2019USD ($)$ / shares	Feb. 28, 2019$ / shares	Jan. 15, 2019$ / sharesshares	Dec. 04, 2018USD ($)$ / sharesshares	Dec. 01, 2018USD ($)$ / shares	Apr. 08, 2018shares	Apr. 07, 2018shares	Mar. 31, 2018shares	Jul. 31, 2017$ / sharesshares	Mar. 31, 2017$ / sharesshares
Common Stock, Shares Authorized (in shares)																		600,000,000				600,000,000	600,000,000		600,000,000						400,000,000	250,000,000	250,000,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)																						7,583,333
Induced Conversion of Convertible Debt Expense | $																						$ 127,059
Exercise of Warrants for Stock, Shares (in shares)																						17,563,000	12,657,875
Class of Warrant or Right, Outstanding (in shares)																		99,790,989				84,538,161	99,790,989										65,883,062
Proceeds from Warrant Exercises | $																						$ 1,274,790
Stock Issued During Period, Shares, Issued for Services (in shares)						2,000,000																2,100,000	4,032,407
Consulting Service Expense | $																						$ 214,000	$ 900,000
Stock Issued During Period, Shares, New Issues (in shares)																						7,668,167
Proceeds from Issuance of Common Stock and Warrants | $					$ 240,000
Prepaid Expense, Current, Total | $																		$ 300,000					$ 300,000
Stock Issued to Settle Royalty Agreement, Shares (in shares)																							600,000
Stock Issued to Settle Royalty Agreement, Value | $																							$ 131,000
Monthly Consulting Fee | $						$ 50,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)																						0
The 2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)																							400,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)																							10 years
Restricted Stock [Member]
Share-based Payment Arrangement, Expense | $																						$ 0	$ 0
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense | $																						103,472	806,282
Share-based Payment Arrangement, Option [Member] | The 2014 Equity Incentive Plan [Member]
Share-based Payment Arrangement, Expense | $																							$ 806,282
SylvaCap Media [Member]
Monthly Consulting Fee | $											$ 10,000
Monthly Consulting Fee, Number of Months											12
Loss on Contract Termination | $									$ 135,000
SylvaCap Media [Member] | Restricted Stock [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)									2,000,000		2,000,000								4,000,000
Loss on Contract Termination | $									$ 135,000
Shares Unissued for Services, Contract Termination (in shares)									2,000,000
Investor [Member]
Stock Issued During Period, Shares, New Issues (in shares)																							277,778
Shares Issued, Price Per Share (in dollars per share) | $ / shares																		$ 0.36					$ 0.36
Conversion of Convertible Notes Into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)																							18,563,885
Debt Conversion, Original Debt, Amount | $																							$ 4,470,000
Debt Conversion, Accrued Interest, Amount | $																							$ 170,971
Private Placement [Member]
Brokerage Fees for Issuance of Common Stock and Warrants | $															$ 600,000			$ 309,620				71,529
Stock Issued During Period, Shares, New Issues (in shares)																							35,878,302
Units of Common Stock and Warrants, Authorized (in shares)												20,000,000	10,000,000															20,000,000	15,000,000
Units of Combined Common Stock and Warrants, Price Per Unit (in dollars per share) | $ / shares													$ 0.25															$ 0.15	$ 0.20
Units of Combined Common Stock and Warrants, Value | $																													$ 3,000,000
Proceeds from Issuance of Private Placement | $															$ 4,400,000			$ 2,072,125				$ 478,696
Units of Combined Common Stock and Warrants, Increase in Number Authorized (in shares)												10,000,000
Maximum [Member]
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) | $ / shares																						$ 0.10	$ 0.325
Maximum [Member] | The 2014 Equity Incentive Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ / shares																		$ 0.60					0.60
Minimum [Member]
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) | $ / shares																						0.035	0.30
Minimum [Member] | The 2014 Equity Incentive Plan [Member]
Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ / shares																		0.37					0.37
Warrants Issued to Investors in Private Placements [Member]
Class of Warrant or Right, Outstanding (in shares)																70,500,000
Class of Warrant or Right, Temporarily Reduced Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																$ 0.10
Class of Warrant or Right, Exercises in Period (in shares)								9,449,750						8,113,250
Proceeds from Warrant Exercises | $								$ 850,478						$ 307,249
Brokerage Fees for Issuance of Common Stock and Warrants | $								94,498						22,566
Inducement Dividend, Exercise of Warrants | $								$ 230,025						$ 32,215							$ 32,215
Warrants Issued to Investors in Private Placements [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares														$ 0.05		0.65					$ 0.05
Warrants Issued to Investors in Private Placements [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares														$ 0.03		$ 0.30					$ 0.03
Warrants Issued In the Private Placement on December 4, 2018 [Member] | Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																		$ 0.30				$ 0.30	$ 0.30					$ 0.30	$ 0.60
Units of Combined Common Stock and Warrants, Warrants Per Unit (in shares)																													1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)																		1				1	1						1
Warrants and Rights Outstanding, Term (Year)																													5 years
Class of Warrant or Right, Issued (in shares)																		15,878,302				3,668,167
Warrants Issued to Broker Participating in Private Placement on December 4, 2018 [Member]
Exercise of Warrants for Stock, Shares (in shares)																							325,125
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares												$ 0.60										$ 0.30
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)												1
Warrants and Rights Outstanding, Term (Year)																						5 years
Class of Warrant or Right, Issued (in shares)													2,000,000									1,954,613
Warrants and Rights Outstanding | $																						$ 132,914
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) | $ / shares																							$ 0.01
Class of Warrant or Right, Expense | $													$ 592,638
Warrants Issued to an Investor on October 10, 2019 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 0.08
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)					1
Warrants and Rights Outstanding, Term (Year)					3 years
Class of Warrant or Right, Issued (in shares)					2,000,000
Warrants and Rights Outstanding | $					$ 110,000
Warrants Issued in March 2017 Convertible Note Offering [Member]
Class of Warrant or Right, Outstanding (in shares)																																			8,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																	$ 0.60	$ 0.30					0.30												$ 0.60
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)																	1
Warrants and Rights Outstanding, Term (Year)																	3 years																		3 years
Class of Warrant or Right, Issued (in shares)																	8,000,000
Warrants Related to July 2017 Convertible Note Offering [Member]
Class of Warrant or Right, Outstanding (in shares)																																		28,804,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																		$ 0.325		$ 0.60			$ 0.325											$ 0.65
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)																				1
Warrants and Rights Outstanding, Term (Year)																				3 years
Class of Warrant or Right, Issued (in shares)																				28,804,000
Warrants Issued In March 2017 and July 2017 Convertible Note Offerings [Member]
Exercise of Warrants for Stock, Shares (in shares)																							12,332,750
Proceeds from Warrant Exercises | $																							$ 3,900,000
Inducement Dividend, Exercise of Warrants | $																		$ 2,900,000					2,900,000
Warrants Issued in the Private Placement on Auagust 10, 2018 [Member] | Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares													$ 0.60
Units of Combined Common Stock and Warrants, Warrants Per Unit (in shares)													1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)													1		1
Warrants and Rights Outstanding, Term (Year)													3 years		3 years
Class of Warrant or Right, Issued (in shares)															20,000,000
Warrants Issued to EMLL Group for Services [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																														$ 0.1125
Warrants and Rights Outstanding | $																														$ 969,197
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											8,000,000
Class of Warrant or Right, Expense | $																							969,197
Warrants Issued to SylvaCap Media for Business Advisory and Consulting Services [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 0.1125
Warrants and Rights Outstanding | $											$ 244,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											2,000,000
Class of Warrant or Right, Expense | $																					$ 162,667		$ 81,333
Common Stock [Member]
Exercise of Warrants for Stock, Shares (in shares)																						17,563,000	12,657,875
Stock Issued During Period, Shares, Issued for Services (in shares)																						2,100,000	4,032,407
Stock Issued During Period, Shares, New Issues (in shares)					4,000,000																	7,668,167	36,156,080
Stock Issued to Settle Royalty Agreement, Shares (in shares)																							600,000
Stock Issued to Settle Royalty Agreement, Value | $																							$ 60
Common Stock [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)															20,000,000			15,878,302				3,668,167
Units of Combined Common Stock and Warrants, Shares Per Unit (in shares)													1																1
Senior Secured Convertible Promissory Note [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares																		$ 0.25					$ 0.25
Debt Instrument, Unamortized Discount, Total | $																		$ 3,464,187					$ 3,464,187
Debt Instrument, Increase (Decrease), Net, Total | $																							$ (1,005,813)
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Conversion, Original Debt, Amount | $	$ 120,000						$ 110,000			$ 170,000
Debt Instrument, Interest Rate, Stated Percentage								8.00%		8.00%																	8.00%
Debt Instrument, Unamortized Discount, Total | $	57,551						9,579			$ 17,225				$ 584,842							584,842
Debt Instrument, Increase (Decrease), Net, Total | $	(62,449)	$ 30,000					(100,421)	$ 100,000		(152,775)
Short-term Debt, Total | $	$ 1,271,863	$ 1,361,863					$ 1,361,863	$ 1,338,057		$ 1,330,000				$ 687,021							$ 687,021			$ 1,269,067
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	3,000,000						1,000,000			1,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 0.04	$ 0.04					$ 0.11	$ 0.11		$ 0.17														$ 0.08			$ 0.17
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)			1,333,333	1,250,000
Debt Conversion, Original Debt, Amount | $			$ 50,000	$ 75,000																		$ 125,000
Debt Instrument, Interest Rate, Stated Percentage																										8.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 0.0375	$ 0.06																						$ 0.17
Debt Instrument, Unamortized Discount, Total | $																										$ 265,000
Short-term Debt, Total | $																						2,735,170
Induced Conversion of Convertible Debt Expense | $			$ 62,353	$ 64,706																		$ 127,059

Note 10 - Capital Transaction_3

Note 10 - Capital Transactions - Warrant Activity (Details) - $ / shares	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Outstanding (in shares)	99,790,989	65,883,062
Warrants issued (in shares)	7,622,780	47,878,302
Warrants issued, exercise price (in dollars per share)	$ 0.30
Warrants exercised (in shares)	(17,563,000)	(12,657,875)
Warrants expired/cancelled (in shares)	(5,312,608)	(1,312,500)
Outstanding (in shares)	84,538,161	99,790,989
Minimum [Member]
Warrants issued, exercise price (in dollars per share)		$ 0.30
Warrants exercised, exercise price (in dollars per share)	$ 0.035	0.30
Warrants expired/cancelled, exercise price (in dollars per share)	0.50	0.50
Maximum [Member]
Warrants issued, exercise price (in dollars per share)		0.60
Warrants exercised, exercise price (in dollars per share)	0.10	0.325
Warrants expired/cancelled, exercise price (in dollars per share)	$ 2	$ 2

Note 11 - Employee Benefit Pl_3

Note 11 - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2015	Feb. 06, 2008	Oct. 27, 18
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	9,450,333
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)	0
Restricted Stock [Member]
Share-based Payment Arrangement, Expense	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	0	0
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense	$ 103,472	$ 806,282
GB Sciences, Inc. 2007 Amended Stock Option Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				4,500,000
The 2014 Equity Compensation Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			8,500,000
GB Sciences, Inc 2018 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)					10,000,000

Note 11 - Employee Benefit Pl_4

Note 11 - Employee Benefit Plan - Assumptions (Details) - Share-based Payment Arrangement, Option [Member]	12 Months Ended
	Mar. 31, 2019
Weighted-average volatility	181.00%
Expected term (in years) (Year)	10 years
Risk-free interest rate	2.74%

Note 11 - Employee Benefit Pl_5

Note 11 - Employee Benefit Plan - Option Activity (Details) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Outstanding, options (in shares)	12,583,334	13,033,334
Outstanding, weighted average exercise price (in dollars per share)	$ 0.28	$ 0.28
Outstanding, weighted average remaining contractual life (Year)	6 years 7 days	7 years 65 days	8 years 76 days
Outstanding, aggregate intrinsic value		$ 43,000	$ 2,646,723
Granted (Note 10) (in shares)		400,000
Granted (Note 10) (in dollars per share)		$ 0.41
Exercised, options (in shares)
Exercised, weighted average exercise price (in dollars per share)
Forfeited, options (in shares)	(1,600,000)	(850,000)
Forfeited, weighted average exercise price (in dollars per share)	$ 0.27	$ 0.24
Outstanding, options (in shares)	10,983,334	12,583,334	13,033,334
Outstanding, weighted average exercise price (in dollars per share)	$ 0.28	$ 0.28	$ 0.28
Fully vested and expected to vest, options (in shares)	10,983,334
Fully vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.28
Exercisable, options (in shares)	10,983,334
Exercisable, weighted average exercise price (in dollars per share)	$ 0.28

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Details Textual)

Jul. 14, 2020USD ($)

Apr. 22, 2020USD ($)

Oct. 01, 2019USD ($)shares

Jun. 06, 2019USD ($)shares

Dec. 06, 2018USD ($)$ / sharesshares

Sep. 18, 2017USD ($)

Dec. 31, 2019USD ($)

Jun. 06, 2019shares

Dec. 31, 2019USD ($)

Mar. 31, 2020USD ($)shares

Mar. 31, 2019USD ($)shares

Mar. 31, 2020USD ($)

Jun. 30, 2020USD ($)

Research and Development Expense, Total

$ 1,543,397

$ 458,790

Monthly Consulting Fee

$ 50,000

Stock Issued During Period, Shares, Issued for Services (in shares) | shares

2,000,000

2,100,000

4,032,407

Quarterly Stock Fee, Shares (in shares) | shares

2,000,000

Consulting Expense Related to Common Stock Payments

$ 180,000

Asset Forfeiture, Charge

$ 200,000

SylvaCap Media [Member]

Monthly Consulting Fee

$ 10,000

Monthly Consulting Fee, Number of Months

12

Loss on Contract Termination

$ 135,000

SylvaCap Media [Member] | Restricted Stock [Member]

Stock Issued During Period, Shares, Issued for Services (in shares) | shares

2,000,000

2,000,000

4,000,000

Loss on Contract Termination

$ 135,000

Shares Unissued for Services, Contract Termination (in shares) | shares

2,000,000

Warrants Issued to SylvaCap Media for Business Advisory and Consulting Services [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares

2,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares

$ 0.1125

Warrants and Rights Outstanding

$ 244,000

Class of Warrant or Right, Expense

$ 162,667

$ 81,333

Payment of Services Provided by Contractor [Member] | Pending Litigation [Member]

Loss Contingency Accrual, Ending Balance

$ 73,050

$ 73,050

Subsequent Event [Member] | Repayment of Iliad Note [Member] | Judicial Ruling [Member]

Debt Instrument, Debt Default, Interest Rate Penalty

15.00%

Litigation Settlement, Amount Awarded to Other Party

$ 3,264,594

Subsequent Event [Member] | Payment of Services Provided by Contractor [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 73,050

Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Subsequent Event [Member]

Debt Instrument, Debt Default, Interest Rate Penalty

10.00%

Debt Instrument, Default, Expense

$ 286,059

Long-term Debt, Gross

$ 3,234,149

Agreement With Louisiana State University AgCenter [Member]

Term of Agreement (Year)

5 years

3 years

Option to Renew Agreement, Amount

2

Term of Agreement, Renewal (Year)

5 years

Research and Development Expense, Total

$ 500,000

$ 250,000

$ 750,000

Note 13 - Deposits and Noncur_2

Note 13 - Deposits and Noncurrent Assets (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Deposits Assets, Noncurrent	$ 91,504	$ 230,651
Research and Development Expense, Total	1,543,397	$ 458,790
Chemicals [Member]
Research and Development Expense, Total	$ 91,600

Note 14 - Related Party Trans_2

Note 14 - Related Party Transactions (Details Textual) - USD ($)	Oct. 01, 2019	Nov. 01, 2017	Mar. 31, 2020	Mar. 31, 2019	Oct. 19, 2018
Due to Officers or Stockholders, Current			$ 586,512
Notes Payable, Related Parties, Current			$ 151,923
Stock Issued During Period, Shares, Issued for Services (in shares)	2,000,000		2,100,000	4,032,407
Other Expenses, Total				$ 3,140,925
THC Note [Member] | Line of Credit [Member]
Line of Credit Facility, Current Borrowing Capacity		$ 300,000
Repayment as Percent of Gross Revenue		25.00%
Proceeds from Related Party Debt					$ 253,034
Officers and Directors [Member]
Due to Officers or Stockholders, Current			$ 586,512
Unpaid Bonuses, Related Parties			80,747
Reimbursement for Business Expense, Related Parties			131,132
Officer [Member]
Unpaid Wages, Related Parties			298,450
Director [Member]
Unpaid Wages, Related Parties			76,183
John Davis [Member]
Notes Payable, Related Parties, Current			$ 151,923
Quantum Shop [Member]
Related Party Transaction, Amounts of Transaction				1,100,000
Electrum Partners, LLC [Member]
Related Party Transaction, Amounts of Transaction				$ 153,329
Stock Issued During Period, Shares, Issued for Services (in shares)				432,407
Restricted Stock or Unit Expense				$ 122,363
THCLLC [Member]
Capitalization of Fair Value of Machinery and Equipment				139,411
Other Expenses, Total				$ 113,623
THCLLC [Member] | Minimum [Member]
Royalty Rates		20.00%
THCLLC [Member] | Maximum [Member]
Royalty Rates		25.00%

Note 15 - Sale of 50% Members_3

Note 15 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Details Textual) - USD ($)	Oct. 15, 2020	Aug. 04, 2020	Nov. 15, 2019	Feb. 12, 2018	Oct. 15, 2020	Oct. 15, 2020	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Aug. 24, 2020
Deconsolidation, Gain (Loss), Amount							$ 4,393,242
Subsequent Event [Member] | John Davis [Member]
Due to Related Parties, Total		$ 189,423
Agreement With Louisiana State University AgCenter [Member] | Subsequent Event [Member]
Annual Research Contributions		$ 250,000
Forecast [Member] | Agreement With Louisiana State University AgCenter [Member]
Annual Research Contribution Commitment Assumed by Counter Party	$ 250,000
Forecast [Member] | Agreement With Louisiana State University AgCenter [Member] | Wellcana Group, LLC [Member]
Annual Research Contribution Commitment Assumed by Counter Party	$ 250,000
Wellcana Note [Member]
Note Receivable, Interest Rate			5.00%
Receivable with Imputed Interest, Discount			$ 1,389,408
Receivable with Imputed Interest, Effective Yield (Interest Rate)			17.00%
Receivable with Imputed Interest, Net Amount, Total			$ 6,610,592				5,224,423		$ 5,224,423
Receivable with Imputed Interest, Face Amount			8,000,000
Financing Receivable, after Allowance for Credit Loss, Total			750,000				7,119,857		7,119,857
Wellcana Note [Member] | COVID 19 [Member]
Notes Receivable, Amount under Forbearance							$ 500,000
Wellcana Note [Member] | Subsequent Event [Member]
Financing Receivable, after Allowance for Credit Loss, Total										$ 500,000
Wellcana Note [Member] | Forecast [Member]
Proceeds from Collection of Notes Receivable and Liabilities Forgiveness					$ 5,224,423
Notes Receivable, Received Consideration, Liabilties Forgiven					324,423	$ 324,423
Proceeds from Collection of Notes Receivable					$ 4,900,000	$ 4,900,000
GB Sciences Louisiana, LLC [Member]
Proceeds from Divestiture of Businesses			8,000,000
Earnout Payments			8,000,000
Deconsolidation, Gain (Loss), Amount			4,393,242
Financing Receivable, after Allowance for Credit Loss, Total			$ 8,000,000
Wellcana Group, LLC [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners				49.99%
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC, Sale of Equity [Member]
Sale of Stock, Percentage of Ownership			50.01%	15.00%
Sale of Stock, Consideration Received on Transaction				$ 3,000,000					$ 7,000,000
Sale of Stock, Percentage of Ownership Available For Sale				35.00%
Sale of Stock, Percentage of Available Stock For Sale, Percent to be Sold Per Transaction				5.00%
Sale of Stock, Consideration Received Per Transaction				$ 1,000,000

Note 15 - Sale of 50% Members_4

Note 15 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Note Receivable (Details) - Wellcana Note [Member] - USD ($)	Mar. 31, 2020	Nov. 15, 2019
June 1, 2020		$ 500,000
September 1, 2020		750,000
December 1, 2020		1,000,000
March 1, 2020		1,250,000
June 1, 2021		1,500,000
September 1, 2021		1,500,000
December 1, 2021		1,500,000
TOTAL PAYMENTS		8,000,000
DISCOUNT ON NOTE RECEIVABLE		(1,389,408)
NET PRESENT VALUE	$ 5,224,423	$ 6,610,592

Note 15 - Sale of 50% Members_5

Note 15 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Deconsolidation (Details) - USD ($)	Nov. 15, 2019	Mar. 31, 2020	Mar. 31, 2019
GAIN ON DECONSOLIDATION		$ 4,393,242
GB Sciences Louisiana, LLC [Member]
Present value of promissory note	$ 6,610,592
Carrying amount of non-controlling interest	8,707,651
TOTAL	15,318,243
Carrying amount of assets	14,715,798
Carrying amount of liabilities	(3,790,797)
Net assets deconsolidated	10,925,001
GAIN ON DECONSOLIDATION	$ 4,393,242

Note 15 - Sale of 50% Members_6

Note 15 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Loss on Modification of Notes Receivable (Details) - USD ($)	2 Months Ended	4 Months Ended	12 Months Ended
	Oct. 15, 2020	Oct. 15, 2020	Mar. 31, 2020	Mar. 31, 2019	Nov. 15, 2019
LOSS ON MODIFICATION OF NOTE RECEIVABLE			$ (1,895,434)
Wellcana Note [Member]
Carrying value of note receivable as of March 31, 2020			6,969,720
Accrued interest as of March 31, 2020			150,137
Total amount receivable as of March 31, 2020			7,119,857		$ 750,000
LOSS ON MODIFICATION OF NOTE RECEIVABLE			$ (1,895,434)
Wellcana Note [Member] | Forecast [Member]
Total cash payments to be made by October 15, 2020	$ 4,900,000	$ 4,900,000
Liabilities to be forgiven upon receipt of October 15, 2020 payment	$ 324,423	324,423
Total receivable (as modified)		$ 5,224,423

Note 16 - Sale of 100% Member_2

Note 16 - Sale of 100% Membership Interest in Teco Facility and Nopah License (Details Textual) - USD ($)	Mar. 24, 2020	Nov. 27, 2019	Nov. 15, 2019	Mar. 31, 2020	Dec. 06, 2019
Teco [Member]
Sale of Stock, Percentage of Ownership	100.00%			100.00%
Proceeds from Divestiture of Businesses	$ 4,000,000
Financing Receivable, after Allowance for Credit Loss, Total	$ 4,000,000
Notes Receivable, Interest Rate	8.00%
Notes Receivable, Term of Monthly Installments (Month)	3 years
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 470,000
Teco Note [Member] | Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity					$ 470,000
Debt Instrument, Interest Rate, Stated Percentage					8.00%
Teco [Member]
Sale of Stock, Percentage of Ownership		75.00%	75.00%
Sale of Stock, Consideration Received on Transaction		$ 3,000,000	$ 3,000,000
Sale of Stock, Additional Earn-out Payments		$ 3,000,000	$ 3,000,000
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership		100.00%
Sale of Stock, Consideration Received on Transaction		$ 300,000

Note 17 - Concentrations (Detai

Note 17 - Concentrations (Details Textual)	12 Months Ended
	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)
Cash, Uninsured Amount	$ 0
Revenue Inculding Discontinued Operations	3,689,697
Revenues, Total	3,120,620	$ 3,454,552
NEVADA
Revenues, Total	3,120,620
LOUISIANA
Revenues, Total	$ 569,077
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Customers	2
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer One [Member]
Concentration Risk, Percentage	12.20%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Two [Member]
Concentration Risk, Percentage	13.80%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]
Concentration Risk, Percentage	29.60%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk, Percentage	28.50%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Three [Member]
Concentration Risk, Percentage	16.90%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | NEVADA
Concentration Risk, Percentage	85.00%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | LOUISIANA
Concentration Risk, Percentage	15.00%

Note 18 - Subsequent Events (De

Note 18 - Subsequent Events (Details Textual) - USD ($)

Oct. 15, 2020

Aug. 04, 2020

Jul. 24, 2020

Jul. 14, 2020

May 07, 2020

Apr. 22, 2020

Apr. 23, 2019

Oct. 15, 2020

Oct. 15, 2020

Aug. 10, 2020

Mar. 31, 2020

Mar. 31, 2019

Aug. 24, 2020

Jun. 30, 2020

Nov. 15, 2019

Mar. 31, 2018

Proceeds from Warrant Exercises

$ 1,274,790

Proceeds from Convertible Debt

$ 2,630,000

1,500,000

Debt Instrument, Face Amount

$ 175,000

Class of Warrant or Right, Outstanding (in shares)

84,538,161

99,790,989

65,883,062

Increase (Decrease) in Accounts Payable, Total

$ 781,589

$ 1,002,846

Gain (Loss) on Modification of Notes Receivable

(1,895,434)

Wellcana Note [Member]

Financing Receivable, after Allowance for Credit Loss, Total

7,119,857

$ 750,000

Receivable with Imputed Interest, Face Amount

8,000,000

Receivable with Imputed Interest, Net Amount, Total

5,224,423

6,610,592

Gain (Loss) on Modification of Notes Receivable

(1,895,434)

Forecast [Member] | Wellcana Group, LLC [Member]

Increase (Decrease) in Accounts Payable, Total

$ (324,423)

Forecast [Member] | Wellcana Note [Member]

Proceeds from Collection of Notes Receivable and Liabilities Forgiveness

5,224,423

Proceeds from Collection of Notes Receivable

$ 4,900,000

$ 4,900,000

Agreement With Louisiana State University AgCenter [Member] | Forecast [Member]

Annual Research Contribution Commitment Assumed by Counter Party

$ 250,000

Payment of Services Provided by Contractor [Member] | Pending Litigation [Member]

Loss Contingency Accrual, Ending Balance

73,050

Warrants Issued to Investor [Member]

Warrants and Rights Outstanding

49,525

GB Sciences Louisiana, LLC [Member]

Financing Receivable, after Allowance for Credit Loss, Total

$ 8,000,000

Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]

Payments for Brokerage Fees

$ 175,000

Debt Instrument, Face Amount

$ 2,765,000

$ 2,765,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Unamortized Discount, Total

$ 265,000

Subsequent Event [Member]

Class of Warrant or Right, Exercises in Period (in shares)

4,991,084

Proceeds from Warrant Exercises

$ 136,082

Brokerage Fees, Exercise of Warrants

$ 15,120

Amendment to the Membership Interest Purchase Agreement, Amount of Debt forgiven in Exchange for Reduction to Note Receivable

$ 4,000,000

Subsequent Event [Member] | Wellcana Note [Member]

Financing Receivable, after Allowance for Credit Loss, Total

$ 500,000

Subsequent Event [Member] | John Davis [Member]

Due to Related Parties, Total

$ 189,423

Subsequent Event [Member] | Agreement With Louisiana State University AgCenter [Member]

Annual Research Contributions

$ 250,000

Subsequent Event [Member] | Repayment of Iliad Note [Member] | Judicial Ruling [Member]

Debt Instrument, Debt Default, Interest Rate Penalty

15.00%

Litigation Settlement, Amount Awarded to Other Party

$ 3,264,594

Subsequent Event [Member] | Payment of Services Provided by Contractor [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 73,050

Subsequent Event [Member] | Warrants Issued to Investor [Member]

Class of Warrant or Right, Outstanding (in shares)

8,002,500

Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)

$ 0.04

Warrants and Rights Outstanding

$ 272,085

Fair Value Adjustment of Warrants

222,560

Subsequent Event [Member] | July 24 Note [Member]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Agreement, Maximum Borrowing Capacity

$ 500,000

Subsequent Event [Member] | Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Issued to Investor on May 7, 2020 [Member]

Proceeds from Convertible Debt

135,000

Payments for Brokerage Fees

15,000

Debt Instrument, Face Amount

$ 150,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Unamortized Discount, Total

$ 150,000

Subsequent Event [Member] | Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]

Debt Instrument, Debt Default, Interest Rate Penalty

10.00%

Debt Instrument, Default, Expense

$ 286,059

Long-term Debt, Gross

$ 3,234,149

Subsequent Event [Member] | Minimum [Member]

Class of Warrant or Right, Exercises in Period, Exercise Price (in dollars per share)

$ 0.03

Subsequent Event [Member] | Maximum [Member]

Class of Warrant or Right, Exercises in Period, Exercise Price (in dollars per share)

$ 0.035

Note 19 - Formation of GBS Gl_2

Note 19 - Formation of GBS Global Biopharma, Inc. (Details Textual) - Asset Purchase Agreement [Member] - GBS Global Biopharma, Inc [Member]	Mar. 15, 2019USD ($)
Due from Related Parties, Total	$ 1,435,700
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Total	475,586
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Total	$ 1,435,700